p_id e_id cell_line modification effect time comment stimuli controls Estrogen GSE1045a MDA-MB-231 breast cancer cells treated with estradiol activation 1 h 2 replicates each, part of time series GSM16943,GSM18491 GSM18492,GSM18493 Estrogen GSE1045b MDA-MB-231 breast cancer cells treated with estradiol activation 2 h 2 replicates each, part of time series GSM16943,GSM18491 GSM18494,GSM18495 Estrogen GSE11467 MCF-7 cells treated with 10 nM estradiol activation 2 h 3 replicates each GSM288961,GSM288962,GSM288963 GSM288964,GSM288965,GSM288966 Estrogen GSE11567a SKBR3 cells treated with 1µM estradiol activation 1 h 3 replicates each, control transfection GSM291218,GSM291219,GSM291220 GSM291224,GSM291225,GSM291226 Estrogen GSE11567b SKBR3 cells treated with 1o µM hydoxytamoxifen unknown 1 h 3 replicates each, control transfection GSM291218,GSM291219,GSM291220 GSM291221,GSM291222,GSM291223 Estrogen GSE11791 MCF-7 cells treated with 100 nM estradiol activation 6 h 3 replicates each GSM298353,GSM298354,GSM298355 GSM298356,GSM298357,GSM298358 Estrogen GSE12261 human smooth muscle cells treated with 3 µM 2-methoxyestradiol activation 4 h 3 replicates each GSM307999,GSM308000,GSM308001 GSM308002,GSM308003,GSM308004 Estrogen GSE13458 MCF-7 cells treated with estradiol activation 3 h 3 replicates each, contain luciferase knockdown GSM339381,GSM339382,GSM339421 GSM339383,GSM339411,GSM339422 Estrogen GSE15717 MCF-7 cells treated with estradiol activation 4 h 3 replicates each GSM393484,GSM393485,GSM393486 GSM393487,GSM393488,GSM393489 Estrogen GSE18592 MCF-7 ER+ breast cancer cells treated with estrogen activation 1 h 3 replicates each GSM462338,GSM462339,GSM462340 GSM462332,GSM462333,GSM462334 Estrogen GSE20081 MCF-7 breast cancer cells treated with estradiol activation 6 h 3 replicates each, contain control siRNA GSM503884,GSM503885,GSM503886 GSM503887,GSM503888,GSM503889 Estrogen GSE22012 MCF-7 breast cancer cells treated with estradiol activation 1 h 4 replicates each GSM547196,GSM547197,GSM547198,GSM547199 GSM547161,GSM547162,GSM547163,GSM547176 Estrogen GSE22593a MDA-MB-231ER+ breast cancer cells treated with estradiol activation 1 h 2 replicates each, part of time series GSM560575,GSM560576 GSM560577,GSM560578 Estrogen GSE22593b MDA-MB-231ER+ breast cancer cells treated with estradiol activation 2 h 2 replicates each, part of time series GSM560575,GSM560576 GSM560579,GSM560580 Estrogen GSE22593c MDA-MB-231ER+ breast cancer cells treated with estradiol activation 4 h 2 replicates each, part of time series GSM560575,GSM560576 GSM560581,GSM560582 Estrogen GSE23445 MCF-7 treated with estradiol activation 4 h 3 replicates each GSM575323,GSM575324,GSM575325 GSM575326,GSM575327,GSM575328 Estrogen GSE23500 human normal breast cells treated with estradiol activation 6 h 3 replicates each GSM575623,GSM575624,GSM575625 GSM575626,GSM575627,GSM575628 Estrogen GSE23610 MCF-7 breast cancer cells treated with 0.1µM estradiol activation 6 h 3 replicates each GSM578941,GSM578942,GSM578943 GSM578944,GSM578945,GSM578946 Estrogen GSE24592 MCF-7 breast cancer cells treated with 10nM estradiol activation 4 h 2-3 replicates each, contain control siRNA GSM606107,GSM606108,GSM606109 GSM606110,GSM606111,GSM606112 Estrogen GSE25314a MCF-7 breast cancer cells treated with 100nM estrogen activation 6 h 4 replicates each, different treatments GSM622757,GSM622761,GSM622765,GSM622769 GSM622758,GSM622762,GSM622766,GSM622770 Estrogen GSE25314b MCF-7 breast cancer cells treated with 1 µM tamoxifen unknown 6 h 4 replicates each, different treatments GSM622757,GSM622761,GSM622765,GSM622769 GSM622760,GSM622764,GSM622768,GSM622772 Estrogen GSE25315 MCF-7 treated with 100nM estrogen activation 6 h 3 replicates each, contain control siRNA GSM622773,GSM622777,GSM622781 GSM622775,GSM622779,GSM622783 Estrogen GSE26459a MCF-7 estrogen sensitive breast cancer cells treated with estrogen activation 4 h 3 replicates each GSM649484,GSM649485,GSM649486 GSM649487,GSM649488,GSM649489 Estrogen GSE26459b MCF-7 estrogen resistant breast cancer cells treated with estrogen activation 4 h 3 replicates each GSM649496,GSM649497,GSM649498 GSM649499,GSM649500,GSM649501 Estrogen GSE26834Est MCF-7 breast cancer cells treated with estradiol activation 3 h 2-3 replicates each GSM659805,GSM659806 GSM659807,GSM659808,GSM659809 Estrogen GSE28006 MCF-7 breast cancer cell line treated with estradiol activation 3 h 2 replicates each, contain siControl RNA GSM692735,GSM692739 GSM692736,GSM692740 Estrogen GSE28645 LY2 breast cancer cell line treated with tamoxifen inhibition 2 h 4 replicates each, contain control siRNA, tamoxifen acts as antagonist in breast cell lines GSM709770,GSM709773,GSM709774,GSM709776 GSM709764,GSM709766,GSM709768,GSM709777 Estrogen GSE3013a endometrial epithelial cells treated with estradiol activation 3 h 2 replicates each on different platforms, different treatments, different tumor stages GSM64885 GSM65278 Estrogen GSE3013b endometrial epithelial cells treated with estradiol activation 3 h 2 replicates each on different platforms, different treatments, different tumor stages GSM65277 GSM65279 Estrogen GSE3013c endometrial epithelial cells treated with tamoxifen unknown 3 h 2 replicates each on different platforms, different treatments, different tumor stages GSM65277 GSM65281 Estrogen GSE3013d endometrial epithelial cells treated with tamoxifen unknown 3 h 2 replicates each on different platforms, different treatments, different tumor stages GSM64885 GSM65280 Estrogen GSE3013f endometrial epithelial cells treated with estradiol activation 3 h 2 replicates each on different platforms, different treatments, different tumor stages GSM65283 GSM65285 Estrogen GSE3013h endometrial epithelial cells treated with tamoxifen unknown 3 h 2 replicates each on different platforms, different treatments, different tumor stages GSM65282 GSM65286 Estrogen GSE3013i endometrial epithelial cells treated with estradiol activation 3 h 2 replicates each on different platforms, different treatments, different tumor stages GSM65288 GSM65290 Estrogen GSE3013j endometrial epithelial cells treated with estradiol activation 3 h 2 replicates each on different platforms, different treatments, different tumor stages GSM65289 GSM65291 Estrogen GSE3013k endometrial epithelial cells treated with tamoxifen unknown 3 h 2 replicates each on different platforms, different treatments, different tumor stages GSM65289 GSM65293 Estrogen GSE3013l endometrial epithelial cells treated with tamoxifen unknown 3 h 2 replicates each on different platforms, different treatments, different tumor stages GSM65288 GSM65292 Estrogen GSE30931 MCF-7 breast cancer cell line treated with estrogen activation 6 h 3 replicates each GSM766676,GSM766677,GSM766678 GSM766679,GSM766680,GSM766681 Estrogen GSE35287a endometrial fibroblasts treated with E2 activation 6 h 1 replicate each, 4 donors GSM865133 GSM865134 Estrogen GSE35287b endometrial fibroblasts treated with E2 activation 6 h 1 replicate each, 4 donors GSM865143 GSM865154 Estrogen GSE35287c endometrial fibroblasts treated with E2 activation 6 h 1 replicate each, 4 donors GSM865145 GSM865146 Estrogen GSE35287d endometrial fibroblasts treated with E2 activation 6 h 1 replicate each, 4 donors GSM865173 GSM865204 Estrogen GSE3834a MCF-7 cells treated with 10 nM estradiol activation 1 h 2 replicates each, different cell lines, part of time series GSM87446,GSM87447 GSM87448 Estrogen GSE3834b MCF-7 cells treated with 10 nM estradiol activation 2 h 2 replicates each, different cell lines, part of time series GSM87446,GSM87447 GSM87449,GSM87450 Estrogen GSE3834c MCF-7 cells treated with 10 nM estradiol activation 4 h 2 replicates each, different cell lines, part of time series GSM87446,GSM87447 GSM87451,GSM87452 Estrogen GSE3834d T47-D cells treated with 10 nM estradiol activation 1 h 2 replicates each, different cell lines, part of time series GSM87495,GSM87496 GSM87497,GSM87498 Estrogen GSE3834e T47-D cells treated with 10 nM estradiol activation 2 h 2 replicates each, different cell lines, part of time series GSM87495,GSM87496 GSM87499,GSM87500 Estrogen GSE3834f T47-D cells treated with 10 nM estradiol activation 4 h 2 replicates each, different cell lines, part of time series GSM87495,GSM87496 GSM87501,GSM87502 Estrogen GSE3834g BT-474 cells treated with 10 nM estradiol activation 2 h 2 replicates each, different cell lines, part of time series GSM87509,GSM87510 GSM87511,GSM87512 Estrogen GSE3834h BT-474 cells treated with 10 nM estradiol activation 4 h 2 replicates each, different cell lines, part of time series GSM87509,GSM87510 GSM87513,GSM87514 Estrogen GSE5258Est MCF-7 cells treated with 10 nM estradiol activation 6 h 1-2 replicates each GSM119000,GSM118794 GSM118730 Estrogen GSE9936a MCF-7 cells treated with 6 nM estradiol activation 4 h 3 replicates each, different treatments, contain control vectors GSM251354,GSM251355,GSM251356 GSM251357,GSM251358,GSM251359 Estrogen GSE9936b MCF-7 cells treated with 6 nM genistein activation 4 h 3 replicates each, different treatments, contain control vector GSM251354,GSM251355,GSM251356 GSM251360,GSM251361,GSM251362 Estrogen GSE9936c MCF-7 cells treated with 300 nM genistein activation 4 h 3 replicates each, different treatments, contain control vector GSM251354,GSM251355,GSM251356 GSM251363,GSM251364 H2O2 GSE21800a 4 lymphoid cell lines pooled treated with 9 µM H2O2 activation 4 h 1 replicate each, time respective control GSM542925 GSM542926 H2O2 GSE21800b 4 lymphoid cell lines pooled treated with 90 µM H2O2 activation 4 h 1 replicate each, time respective control GSM542925 GSM542927 H2O2 GSE21800c 4 lymphoid cell lines pooled treated with 900 µM H2O2 activation 4 h 1 replicate each, time respective control GSM542925 GSM542928 H2O2 GSE22463a PBMCs from >50 year old female treated with H2O2 activation 3 h 1 replicate each, time series, 8 older individuals GSM558027 GSM558035 H2O2 GSE22463b PBMCs from >50 year old female treated with H2O2 activation 3 h 1 replicate each, time series, 8 older individuals GSM558028 GSM558036 H2O2 GSE22463c PBMCs from >50 year old female treated with H2O2 activation 3 h 1 replicate each, time series, 8 older individuals GSM558029 GSM558037 H2O2 GSE22463d PBMCs from >50 year old female treated with H2O2 activation 3 h 1 replicate each, time series, 8 older individuals GSM558030 GSM558038 H2O2 GSE22463e PBMCs from >50 year old female treated with H2O2 activation 3 h 1 replicate each, time series, 8 older individuals GSM558031 GSM558039 H2O2 GSE22463f PBMCs from >50 year old female treated with H2O2 activation 3 h 1 replicate each, time series, 8 older individuals GSM558032 GSM558040 H2O2 GSE22463g PBMCs from >50 year old female treated with H2O2 activation 3 h 1 replicate each, time series, 8 older individuals GSM558033 GSM558041 H2O2 GSE22463h PBMCs from >50 year old female treated with H2O2 activation 3 h 1 replicate each, time series, 8 older individuals GSM558034 GSM558042 H2O2 GSE22463i PBMCs from >50 year old female treated with H2O2 activation 6 h 1 replicate each, time series, 8 older individuals GSM558027 GSM558043 H2O2 GSE22463j PBMCs from >50 year old female treated with H2O2 activation 6 h 1 replicate each, time series, 8 older individuals GSM558028 GSM558044 H2O2 GSE22463k PBMCs from >50 year old female treated with H2O2 activation 6 h 1 replicate each, time series, 8 older individuals GSM558029 GSM558045 H2O2 GSE22463l PBMCs from >50 year old female treated with H2O2 activation 6 h 1 replicate each, time series, 8 older individuals GSM558030 GSM558046 H2O2 GSE22463m PBMCs from >50 year old female treated with H2O2 activation 6 h 1 replicate each, time series, 8 older individuals GSM558031 GSM558047 H2O2 GSE22463n PBMCs from >50 year old female treated with H2O2 activation 6 h 1 replicate each, time series, 8 older individuals GSM558032 GSM558048 H2O2 GSE22463o PBMCs from >50 year old female treated with H2O2 activation 6 h 1 replicate each, time series, 8 older individuals GSM558033 GSM558049 H2O2 GSE22463p PBMCs from >50 year old female treated with H2O2 activation 6 h 1 replicate each, time series, 8 older individuals GSM558034 GSM558050 H2O2 GSE5339a ATCC 16Lu ( human lung fibroblasts) H2O2 treatment activation 1 h time series 1, 4, 12, 24 h GSM120303,GSM120304,GSM120305 GSM120318,GSM120319,GSM120320 H2O2 GSE5339b ATCC 16Lu ( human lung fibroblasts) H2O2 treatment activation 4 h time series 1, 4, 12, 24 h GSM120309,GSM120310,GSM120311 GSM120324,GSM120325,GSM120326 Hippo GSE120512 Human Ewing Sarcoma cell line SK-N-MC YAP siRNA inhibition 72 h 4 replicates GSM3402289,GSM3402290,GSM3402291,GSM3402292 GSM3402293,GSM3402294,GSM3402295,GSM3402296 Hippo GSE121732 Human heptocarcioma cell line HepG2 YAP siRNA inhibition 24 h 3 replicates control, 2 siRNAs 3 replicates each combined (supposed to have good overlap according to paper, not shown!!!) GSM3444835,GSM3444836,GSM3444837 GSM3444838,GSM3444839,GSM3444840,GSM3444841,GSM3444842,GSM3444843 Hippo GSE35004 Hep3B YAP siRNA inhibition 24h 3 replicates GSM860172,GSM860173,GSM860174 GSM860178,GSM860179,GSM860180 Hippo GSE49384a HaCaT YAP+TAZ siRNA inhibition 96h 2 replicates, control is LATS2/NF2 kd, two cell lines GSM1198655,GSM1198656 GSM1198657,GSM1198658 Hippo GSE49384b HepG2 YAP+TAZ siRNA inhibition 96h 2 replicates, control is LATS2/NF2 kd, two cell lines GSM1198661,GSM1198662 GSM1198663,GSM1198664 Hippo GSE49406 HEK293 YAP shRNA inhibition unspecified 3 replicates GSM1198995,GSM1198996,GSM1198997 GSM1199001,GSM1199002,GSM1199003 Hippo GSE56445 Breast cancer cell MDA-MB-231-LM2-4 YAP+TAZ siRNA inhibition 48h 3 replicates, in 24h-TGFß stimulation background GSM1361645,GSM1361646,GSM1361647 GSM1361648,GSM1361649,GSM1361650 Hippo GSE57257 Ovarian cancer cell line OVCAR5 YAP siRNA inhibition 56 h 3 replicates control, 2 siRNAs 3 replicates each combined GSM1378039,GSM1378040,GSM1378041 GSM1378029,GSM1378030,GSM1378031,GSM1378027,GSM1378028,GSM1378033 Hippo GSE59229 MCF10A YAP+TAZ siRNA inhibition 48 h 4 replicates control, 2 siRNAs 4 replicates each combined GSM1431010,GSM1431011,GSM1431012,GSM1431013 GSM1431014,GSM1431015,GSM1431016,GSM1431017,GSM1431018,GSM1431019,GSM1431020,GSM1431021 Hippo GSE60579a mammary epithelial cell line MCF-10A Tamoxifen-inducible YAP construct activation 2 h 2 replicates, second time point as seperate experiment GSM1482830,GSM1482836 GSM1482833,GSM1482839 Hippo GSE60579b mammary epithelial cell line MCF-10A Tamoxifen-inducible YAP construct activation 6 h 2 replicates, second time point as seperate experiment GSM1482831,GSM1482837 GSM1482834,GSM1482840 Hippo GSE61767 HuCCT1 cholangiocarcinoma cell line YAP shRNA inhibition 72 h four replicates GSM1513635,GSM1513636,GSM1513637,GSM1513638 GSM1513639,GSM1513640,GSM1513641,GSM1513642 Hippo GSE61989 Human umbilical vein endothelial cell YAP siRNA inhibition 30 h 4 replicates control, 2 siRNAs 4 replicates each combined (showed strong overlap in original paper) GSM1517967,GSM1517968,GSM1517969,GSM1517970 GSM1517971,GSM1517972,GSM1517973,GSM1517974,GSM1517975,GSM1517976,GSM1517977,GSM1517978 Hippo GSE66082 MDA-MB-231 cells YAP siRNA inhibition 48 h 4 replicates control, 2 siRNAs 4 replicates each combined GSM1614041,GSM1614042,GSM1614043,GSM1614044 GSM1614045,GSM1614046,GSM1614047,GSM1614048,GSM1614049,GSM1614050,GSM1614051,GSM1614052 Hippo GSE66949 Oral squamous cell carcinoma SCC2 YAP+TAZ siRNA inhibition 48 h 3 replicates GSM1634772,GSM1634773,GSM1634774 GSM1634781,GSM1634782,GSM1634783 Hippo GSE68599a Melanoma cell line SKMEL28 made PLX4032 resistant YAp/TAZ si RNA inhibition 72 h 2 replicates, second cell line as seperate experiment GSM1898757,GSM1898758 GSM1898759,GSM1898760 Hippo GSE68599b Melanoma cell line WM3248 made PLX4032 resistant YAp/TAZ si RNA inhibition 72 h 2 replicates, second cell line as seperate experiment GSM1898761,GSM1898762 GSM1898763,GSM1898764 Hippo GSE93400 Small cell lung cancer cell line SBC5 YAP siRNA inhibition 48 h no replicates, this cell line has no TAZ and therefore YAP kd will show better Hippo-like response than SBC3 GSM2452693 GSM2452694 Hypoxia GSE1056 Hep3B cells treated with 1% oxygen hypoxia activation 2 h 2 replicates each GSM17082,GSM17083 GSM17088,GSM17089 Hypoxia GSE106959 medulloblastoma cell line D283-Med treated with 1% oxygen activation 6 h 3 replicates GSM2858315,GSM2858319,GSM2858323 GSM2858316,GSM2858320,GSM2858324 Hypoxia GSE109233a human adult pericyte cell cultures. Sub-vetricular zone (SVZ) pericytes from a temporal lobe epilepsy treated with 0.5-0.7% oxygen activation 2 h 4 replicates GSM2935663,GSM2935664,GSM2935665,GSM2935666 GSM2935655,GSM2935656,GSM2935657,GSM2935658 Hypoxia GSE109233b human adult pericyte cell cultures. Sub-vetricular zone (SVZ) pericytes from a temporal lobe epilepsy treated with 0.5-0.7% oxygen activation 6 h 3 replicates GSM2935677,GSM2935678,GSM2935679 GSM2935671,GSM2935672,GSM2935673 Hypoxia GSE17188a MDA-MB-231 LM2 cells treated with 1% oxygen hypoxia activation 6 h 2 replicates each, different cell lines GSM429891,GSM429892 GSM429893,GSM429894 Hypoxia GSE17188b MDA-MB-231 SCP2 cells treated with 1% oxygen hypoxia activation 6 h 2 replicates each, different cell lines GSM429897,GSM429898 GSM429899,GSM429900 Hypoxia GSE19123 MCF-7 cells treated with 1% oxygen hypoxia activation 4 h 5 replicates each GSM474352,GSM474353,GSM474354,GSM474355,GSM474356 GSM474367,GSM474368,GSM474369,GSM474370,GSM474371 Hypoxia GSE22469 Rhabdomyosarcoma cells (SJRH30) treated with 1% oxygen activation 6 h 2 replicates GSM558109,GSM558110 GSM558111,GSM558112 Hypoxia GSE27813 MCF-7 cells treated with 1% oxygen hypoxia activation 6 h 2 replicates each, contain control shRNA GSM686788,GSM686789 GSM686790,GSM686791 Hypoxia GSE28603a SGBS adipocytes treated with 1% oxygen hypoxia activation 3 h 3 replicates each, part of time series GSM707909,GSM707913,GSM707917 GSM707910,GSM707914,GSM707918 Hypoxia GSE28603b SGBS adipocytes treated with 1% oxygen hypoxia activation 6 h 3 replicates each, part of time series GSM707909,GSM707913,GSM707917 GSM707911,GSM707915,GSM707919 Hypoxia GSE30019a MCF7 treated with 0.5% oxygen activation 1 h three replicates, time series GSM742971,GSM742972,GSM742973 GSM742974,GSM742975,GSM742976 Hypoxia GSE30019b MCF7 treated with 0.5% oxygen activation 4 h three replicates, time series GSM742971,GSM742972,GSM742973 GSM742977,GSM742978,GSM742979 Hypoxia GSE30499 U2OS treated with 0.1% oxygen activation 3 h no replicates GSM756510 GSM756514 Hypoxia GSE33521 HeLa cells treated with 1% oxygen hypoxia activation 6 h 2 replicates each GSM829385,GSM829386 GSM829387,GSM829388 Hypoxia GSE35819a human embryonic stem cell HS401 treated with 4% oxygen activation 2 h no replicates, three cell lines GSM875714 GSM875713 Hypoxia GSE35819b human embryonic stem cell HS360 treated with 4% oxygen activation 2 h no replicates, three cell lines GSM875720 GSM875719 Hypoxia GSE35819c human embryonic stem cell H9 treated with 4% oxygen activation 2 h no replicates, three cell lines GSM875726 GSM875725 Hypoxia GSE35932a HUVEC treated with 1% oxygen activation 1 h no replicates, time series GSM877586 GSM921645 Hypoxia GSE35932b HUVEC treated with 1% oxygen activation 4 h no replicates, time series GSM877586 GSM921647 Hypoxia GSE41491a DU145 treated with 0% oxygen activation 1 h no replicate, several time points, several cell lines GSM1018170 GSM1018171 Hypoxia GSE41491b DU145 treated with 0% oxygen activation 4 h no replicate, several time points, several cell lines GSM1018170 GSM1018173 Hypoxia GSE41491c HT29 treated with 0% oxygen activation 1 h no replicate, several time points, several cell lines GSM1018178 GSM1018179 Hypoxia GSE41491d HT29 treated with 0% oxygen activation 4 h no replicate, several time points, several cell lines GSM1018178 GSM1018181 Hypoxia GSE41491e MCF7 treated with 0% oxygen activation 1 h no replicate, several time points, several cell lines GSM1018186 GSM1018187 Hypoxia GSE41491f MCF7 treated with 0% oxygen activation 4 h no replicate, several time points, several cell lines GSM1018186 GSM1018189 Hypoxia GSE46263a human umbilical vein endothelial cells (HUVEC) treated with CoCl2 (chemically induced hypoxia) activation 1 h 3 replicates GSM1127793,GSM1127817,GSM1127839 GSM1127796,GSM1127818,GSM1127840 Hypoxia GSE46263b human umbilical vein endothelial cells (HUVEC) treated with CoCl2 (chemically induced hypoxia) activation 3 h 3 replicates GSM1127793,GSM1127817,GSM1127839 GSM1127797,GSM1127819,GSM1127841 Hypoxia GSE5258 MCF7 cells treated with 0.1mM cobalt chloride activation 6 h 3 replicates each, cobald cloride induces HIF1 GSM118799,GSM118848,GSM118922 GSM118850,GSM118855,GSM118928 Hypoxia GSE59729a hepatocarcinoma cell line Huh-7 treated with 1% oxygen activation 3 h 2-3 replicates, second time point included GSM1444515,GSM1444516 GSM1444517,GSM1444518,GSM1444519 Hypoxia GSE59729b hepatocarcinoma cell line Huh-7 treated with 1% oxygen activation 6 h 2 replicates, second time point included GSM1444515,GSM1444516 GSM1444523,GSM1444524 Hypoxia GSE60432 Human placental trophoblasts treated with 0% oxygen activation 6 h 3 replicates (from 3 donors probably?) GSM1479785,GSM1479801,GSM1479812 GSM1479786,GSM1479802,GSM1479813 Hypoxia GSE60729 human monocyte-derived dendritic cells treated with 1% oxygen activation 6 h 3 replicates GSM1486351,GSM1486352,GSM1486353 GSM1486363,GSM1486364,GSM1486365 Hypoxia GSE65271 human placenta cell line hHTR8/SVneo treated with 1% oxygen activation 6 h 3-4 replicates GSM1591517,GSM1591518,GSM1591519,GSM1591520 GSM1591514,GSM1591515,GSM1591516 Hypoxia GSE71967 Human Umbilical Vein Endothelial Cells (HUVEC) treated with 2% oxygen activation 4 h no replicate GSM1848696 GSM1848683 Hypoxia GSE79069 human cervical adenocarcinoma HeLa cells treated with 1% oxygen activation 6 h 3 replicates GSM2084870,GSM2084871,GSM2084872 GSM2084873,GSM2084874,GSM2084875 Hypoxia GSE89891 human breast cancer cell line MCF7 treated with 1% oxygen activation 2 h 3 replicates GSM2392640,GSM2392641,GSM2392643 GSM2392649,GSM2392650,GSM2392651 IL-1 GSE22325 HUVECs treated with 100U IL-1b activation 4 h 1 replicate each GSM555847 GSM555851 IL-1 GSE32390a skin fibroblasts treated with 20 ng/ml IL-1b activation 4 h 1 replicate each, 3 donors GSM801681 GSM801669 IL-1 GSE32390b skin fibroblasts treated with 20 ng/ml IL-1b activation 4 h 1 replicate each, 3 donors GSM801680 GSM801678 IL-1 GSE32390c skin fibroblasts treated with 20 ng/ml IL-1b activation 4 h 1 replicate each, 3 donors GSM801677 GSM801670 IL-1 GSE8515IL1 Human monocyte-derived macrophages with IL-1 (15 ng/ml) activation 4 h 5 replicates each GSM211500,GSM211501,GSM211502,GSM211503,GSM211504 GSM211505,GSM211506,GSM211507,GSM211508,GSM211509 IL-1 GSE9120a Cultured epidermal keratinocytes treated with 25 ng/ml human recombinant IL-1 activation 1 h GSM230880 GSM230879 IL-1 GSE9120b Cultured epidermal keratinocytes treated with 25 ng/ml human recombinant IL-1 activation 4 h GSM230881 GSM230882 IL-1 GSE973a HUVEC treated with 100 U/ml human IL-1 activation 0.5 h time series 3 time points GSM15389 GSM15390 IL-1 GSE973b HUVEC treated with 100 U/ml human IL-1 activation 1 h time series 3 time points GSM15389 GSM15391 IL-1 GSE973c HUVEC treated with 100 U/ml human IL-1 activation 2.5 h time series 3 time points GSM15389 GSM15392 Insulin GSE21727 trabecular bone cells treated with IGF-1 activation 2 h 3 replicates each GSM542107,GSM542108,GSM542109 GSM542098,GSM542099,GSM542100 Insulin GSE21989a HUVECs treated with Insulin activation 0.66 h 1 replicate each, part of time series GSM546910 GSM546915 Insulin GSE21989b HUVECs treated with Insulin activation 1.66 h 1 replicate each, part of time series GSM546911 GSM546916 Insulin GSE21989c HUVECs treated with Insulin activation 3.33 h 1 replicate each, part of time series GSM546912 GSM546917 Insulin GSE21989d HUVECs treated with Insulin activation 5.66 h 1 replicate each, part of time series GSM546913 GSM546918 Insulin GSE24422a hMSC adipocytes, mixed fraction treated with 20 nM Insulin activation 5 h 2 replicates each, different fractions of cells GSM601621,GSM601622 GSM601623,GSM601624 Insulin GSE24422b hMSC adipocytes, adipocyte fraction treated with 20 nM Insulin activation 5 h 2 replicates each, different fractions of cells GSM601629,GSM601630 GSM601631,GSM601632 Insulin GSE24422c hMSC adipocytes, stromal fraction treated with 20 nM Insulin activation 5 h 2 replicates each, different fractions of cells GSM601637,GSM601638 GSM601639,GSM601640 Insulin GSE26834 MCF-7 breast cancer cells treated with IGF-1 activation 3 h 2 replicates for control, 3 replicates for treatment GSM659805,GSM659806 GSM659810,GSM659811,GSM659812 Insulin GSE30524 RPMI 8266 cells treated with 0.375µM picropodophyllin, IGF1R inhibitor inhibition 6 h 1 replicate each GSM756954 GSM756956 Insulin GSE9105a primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 0.5 h 1 replicate each, part of time series, 12 donors GSM230429 GSM230430 Insulin GSE9105b primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 4 h 1 replicate each, part of time series, 12 donors GSM230429 GSM230431 Insulin GSE9105c primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 0.5 h 1 replicate each, part of time series, 12 donors GSM230432 GSM230433 Insulin GSE9105d primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 4 h 1 replicate each, part of time series, 12 donors GSM230432 GSM230434 Insulin GSE9105e primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 0.5 h 1 replicate each, part of time series, 12 donors GSM230435 GSM230436 Insulin GSE9105f primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 4 h 1 replicate each, part of time series, 12 donors GSM230435 GSM230437 Insulin GSE9105g primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 4 h 1 replicate each, part of time series, 12 donors GSM230438 GSM230440 Insulin GSE9105h primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 0.5 h 1 replicate each, part of time series, 12 donors GSM230438 GSM230439 Insulin GSE9105i primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 0.5 h 1 replicate each, part of time series, 12 donors GSM230441 GSM230442 Insulin GSE9105j primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 4 h 1 replicate each, part of time series, 12 donors GSM230441 GSM230443 Insulin GSE9105k primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 0.5 h 1 replicate each, part of time series, 12 donors GSM230444 GSM230445 Insulin GSE9105l primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 4 h 1 replicate each, part of time series, 12 donors GSM230444 GSM230446 Insulin GSE9105m primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 4 h 1 replicate each, part of time series, 12 donors GSM230447 GSM230449 Insulin GSE9105n primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 0.5 h 1 replicate each, part of time series, 12 donors GSM230447 GSM230448 Insulin GSE9105o primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 0.5 h 1 replicate each, part of time series, 12 donors GSM230450 GSM230451 Insulin GSE9105p primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 4 h 1 replicate each, part of time series, 12 donors GSM230450 GSM230452 Insulin GSE9105q primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 4 h 1 replicate each, part of time series, 12 donors GSM230453 GSM230455 Insulin GSE9105r primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 0.5 h 1 replicate each, part of time series, 12 donors GSM230453 GSM230454 Insulin GSE9105s primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 0.5 h 1 replicate each, part of time series, 12 donors GSM230456 GSM230457 Insulin GSE9105t primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 4 h 1 replicate each, part of time series, 12 donors GSM230456 GSM230458 Insulin GSE9105u primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 4 h 1 replicate each, part of time series, 12 donors GSM230459 GSM230461 Insulin GSE9105v primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 0.5 h 1 replicate each, part of time series, 12 donors GSM230459 GSM230460 Insulin GSE9105w primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 0.5 h 1 replicate each, part of time series, 12 donors GSM230462 GSM230463 Insulin GSE9105x primary muscle cells treated with euglycemic hyperinsulinemic clamp activation 4 h 1 replicate each, part of time series, 12 donors GSM230462 GSM230464 JAK-STAT GSE10685 skeletal muscle biopsies patients treated with IL-6 infusion activation 3 h 3 donors GSM269808,GSM269811,GSM269932 GSM269809,GSM269834,GSM269933 JAK-STAT GSE12664 A549 cells treated with IFNb activation 6 h 3 replicates GSM317891,GSM317903,GSM317915 GSM317927,GSM317928,GSM317929 JAK-STAT GSE1432a primary human microglial cells Y20 treated with IFN-gamma (respective time control) activation 1 h GSM26928 GSM23899 JAK-STAT GSE1432b primary human microglial cells B18 treated with IFN-gamma (respective time control) activation 1 h GSM26926 GSM23887 JAK-STAT GSE1432c primary human microglial cells W treated with IFN-gamma (respective time control) activation 1 h GSM26927 GSM23895 JAK-STAT GSE1432d primary human microglial cells O treated with IFN-gamma (respective time control) activation 1 h GSM26925 GSM23893 JAK-STAT GSE14632a HepG2 hepatocarcinoma cell line treated with 20ng/ml IL-6 activation 1 h 2 replicates, part of time series, 4h serum starvation before treatment GSM636652,GSM636653 GSM636654,GSM636655 JAK-STAT GSE14632b HepG2 hepatocarcinoma cell line treated with 20ng/ml IL-6 activation 2 h 2 replicates, part of time series, 4h serum starvation before treatment GSM636652,GSM636653 GSM636656,GSM636657 JAK-STAT GSE14632c HepG2 hepatocarcinoma cell line treated with 20ng/ml IL-6 activation 4 h 2 replicates, part of time series, 4h serum starvation before treatment GSM636652,GSM636653 GSM636658,GSM636659 JAK-STAT GSE15743a primary NK cells treated with 1 ng/ml IFNa-2b activation 6 h 1 replicate, 2 concentrations GSM394093 GSM394094 JAK-STAT GSE15743b primary NK cells treated with 100 ng/ml IFNa-2b activation 6 h 1 replicate, 2 concentrations GSM394093 GSM394095 JAK-STAT GSE16251a primary PBMCs treated with IFNa activation 4 h 1 replicate, time respective control, part of time GSM409172 GSM409178 JAK-STAT GSE16251b primary PBMCs treated with IFNa activation 0.5 h 1 replicate, time respective control, part of time GSM409180 GSM409181 JAK-STAT GSE16251c primary PBMCs treated with IIL12 activation 0.5 h 1 replicate, time respective control, part of time GSM409180 GSM409183 JAK-STAT GSE16251d primary PBMCs treated with IIL12 activation 1 h 1 replicate, time respective control, part of time GSM409182 GSM409157 JAK-STAT GSE16251e primary PBMCs treated with IIL12 activation 4 h 1 replicate, time respective control, part of time GSM409178 GSM409152 JAK-STAT GSE16252a primary PBMCs treated with 0.6 pM IFNg activation 0.5 h 1 replicate, time respective control, part of time and concentration series GSM409200 GSM409188 JAK-STAT GSE16252b primary PBMCs treated with 0.6 pM IFNg activation 1 h 1 replicate, time respective control, part of time and concentration series GSM409199 GSM409190 JAK-STAT GSE16252c primary PBMCs treated with 0.6 pM IFNg activation 2 h 1 replicate, time respective control, part of time and concentration series GSM409194 GSM409187 JAK-STAT GSE16252d primary PBMCs treated with 0.6 pM IFNg activation 4 h 1 replicate, time respective control, part of time and concentration series GSM409197 GSM409213 JAK-STAT GSE16252e primary PBMCs treated with 60 pM IFNg activation 0.5 h 1 replicate, time respective control, part of time and concentration series GSM409200 GSM409211 JAK-STAT GSE16252f primary PBMCs treated with 60 pM IFNg activation 1 h 1 replicate, time respective control, part of time and concentration series GSM409199 GSM409209 JAK-STAT GSE16252g primary PBMCs treated with 60 pM IFNg activation 2 h 1 replicate, time respective control, part of time and concentration series GSM409194 GSM409212 JAK-STAT GSE16252h primary PBMCs treated with 60 pM IFNg activation 4 h 1 replicate, time respective control, part of time and concentration series GSM409197 GSM409208 JAK-STAT GSE16252i primary PBMCs treated with 0.006 pM IFNg activation 0.5 h 1 replicate, time respective control, part of time and concentration series GSM409200 GSM409193 JAK-STAT GSE16252j primary PBMCs treated with 0.006 pM IFNg activation 1 h 1 replicate, time respective control, part of time and concentration series GSM409199 GSM409191 JAK-STAT GSE16252k primary PBMCs treated with 0.006 pM IFNg activation 2 h 1 replicate, time respective control, part of time and concentration series GSM409194 GSM409201 JAK-STAT GSE16252l primary PBMCs treated with 0.006 pM IFNg activation 4 h 1 replicate, time respective control, part of time and concentration series GSM409197 GSM409214 JAK-STAT GSE16253a primary monocytes treated with 0.6 pM IFNg activation 0.5 h 1 replicate, time respective control, part of time series, different cell lines GSM409215 GSM409267 JAK-STAT GSE16253b primary monocytes treated with 0.6 pM IFNg activation 4 h 1 replicate, time respective control, part of time series, different cell lines GSM409228 GSM409257 JAK-STAT GSE16253c primary monocytes treated with 0.6 pM IFNg activation 1 h 1 replicate, time respective control, part of time series, different cell lines GSM409269 GSM409275 JAK-STAT GSE16253d primary B cells treated with 0.6 pM IFNg activation 0.5 h 1 replicate, time respective control, part of time series, different cell lines GSM409250 GSM409219 JAK-STAT GSE16253e primary B cells treated with 0.6 pM IFNg activation 1 h 1 replicate, time respective control, part of time series, different cell lines GSM409251 GSM409290 JAK-STAT GSE16253f primary B cells treated with 0.6 pM IFNg activation 4 h 1 replicate, time respective control, part of time series, different cell lines GSM409234 GSM409279 JAK-STAT GSE16253g primary CD4+ T cells treated with 0.6 pM IFNg activation 0.5 h 1 replicate, time respective control, part of time series, different cell lines GSM409237 GSM409276 JAK-STAT GSE16253h primary CD4+ T cells treated with 0.6 pM IFNg activation 1 h 1 replicate, time respective control, part of time series, different cell lines GSM409261 GSM409264 JAK-STAT GSE16253j primary NK cells treated with 0.6 pM IFNg activation 4 h 1 replicate, time respective control, part of time series, different cell lines GSM409218 GSM409271 JAK-STAT GSE16253k primary NK cells treated with 0.6 pM IFNg activation 1 h 1 replicate, time respective control, part of time series, different cell lines GSM409223 GSM409273 JAK-STAT GSE16253l primary NK cells treated with 0.6 pM IFNg activation 0.5 h 1 replicate, time respective control, part of time series, different cell lines GSM409235 GSM409274 JAK-STAT GSE16253m primary CD8+ T cells treated with 0.6 pM IFNg activation 0.5 h 1 replicate, time respective control, part of time series, different cell lines GSM409241 GSM409281 JAK-STAT GSE16253n primary CD8+ T cells treated with 0.6 pM IFNg activation 1 h 1 replicate, time respective control, part of time series, different cell lines GSM409256 GSM409243 JAK-STAT GSE16253o primary CD8+ T cells treated with 0.6 pM IFNg activation 4 h 1 replicate, time respective control, part of time series, different cell lines GSM409249 GSM409282 JAK-STAT GSE16385 primary macrophage treated with IL-4 activation 4 h 1 replicate, respective time control GSM411184 GSM411186 JAK-STAT GSE16450a immature BE(2)-C neuroblastoma cell line treated with IFNa-A/D activation 6 h 3 replicates GSM413549,GSM413550,GSM413551 GSM413552,GSM413553,GSM413554 JAK-STAT GSE16450b mature BE(2)-C neuroblastoma cell line treated with IFNa-A/D activation 6 h 3 replicates GSM413558,GSM413559,GSM413560 GSM413561,GSM413562,GSM413563 JAK-STAT GSE16755 macrophages treated with IFNa activation unknown 3 replicates GSM419987,GSM419988,GSM419989 GSM419990,GSM419991,GSM419992 JAK-STAT GSE19082a HMEC (human microvascular endothelial cells) treated with IFN-gamma 1 ng/ml (respective time control) activation 3 h 4 replicates each two different treatments GSM472434,GSM472438,GSM472442,GSM472446 GSM472436,GSM472440,GSM472444,GSM472448 JAK-STAT GSE19082b HMEC (human microvascular endothelial cells) treated with IL-6 50 U/ml (respective time control) activation 1 h 4 replicates each, two different treatments GSM472434,GSM472438,GSM472442,GSM472446 GSM472435,GSM472439,GSM472443,GSM472447 JAK-STAT GSE1925a primary human CD14+ macrophages Pool1 treated with IFN-gamma activation 3 h GSM34595 GSM34596 JAK-STAT GSE1925b primary human CD14+ macrophages Pool2 treated with IFN-gamma activation 3 h GSM34601 GSM34602 JAK-STAT GSE1925c primary human CD14+ macrophages Pool3 treated with IFN-gamma activation 3 h GSM34607 GSM34608 JAK-STAT GSE20198a activated cord blood CD4+ T cells treated with IFNa activation 2 h 1 replicate, part of time series GSM506700 GSM506701 JAK-STAT GSE20198b activated cord blood CD4+ T cells treated with IFNa activation 6 h 1 replicate, part of time series GSM506702 GSM506703 JAK-STAT GSE20272a SKOV-3 ovarian cancer cell line treated with IL-6 activation 1 h 1 replicate, 2 different cell lines GSM508291 GSM508292 JAK-STAT GSE20272b Caov-3 ovarian cancer cell line treated with IL-6 activation 1 h 1 replicate, 2 different cell lines GSM508294 GSM508295 JAK-STAT GSE21760a HeLa cells treated with IFNg activation 2 h 1 replicate, part of time series GSM542389 GSM542390 JAK-STAT GSE21760b HeLa cells treated with IFNg activation 4 h 1 replicate, part of time series GSM542389 GSM542391 JAK-STAT GSE21760c HeLa cells treated with IFNg activation 6 h 1 replicate, part of time series GSM542389 GSM542392 JAK-STAT GSE22325a HUVECs treated with 100 U/ml IL-3 activation 4 h 1 replicate each, time resolved control GSM555847 GSM555854 JAK-STAT GSE22325b HUVECs treated with 100 U/ml IL-6 activation 4 h 1 replicate each, time resolved control GSM555847 GSM555858 JAK-STAT GSE23307a primary B cells treated with IFN-b activation 3 h 1 replicate each, respective time control, 2 individuals GSM571900 GSM571899 JAK-STAT GSE23307b primary B cells treated with IFN-b activation 3 h 1 replicate each, respective time control, 2 individuals GSM571904 GSM571903 JAK-STAT GSE23307c primary monocytes treated with IFN-b activation 3 h 1 replicate each, respective time control, 2 individuals GSM571902 GSM571901 JAK-STAT GSE23591a L1236 lymphoma derived cell line treated with 40 ng/ml IL-13 activation 0.5 h 1 replicate, time resolved controls, part of time series GSM578575 GSM578576 JAK-STAT GSE23591b L1236 lymphoma derived cell line treated with 40 ng/ml IL-13 activation 1 h 1 replicate, time resolved controls, part of time series GSM578577 GSM578578 JAK-STAT GSE23591c L1236 lymphoma derived cell line treated with 40 ng/ml IL-13 activation 1.5 h 1 replicate, time resolved controls, part of time series GSM578579 GSM578580 JAK-STAT GSE23591d L1236 lymphoma derived cell line treated with 40 ng/ml IL-13 activation 2 h 1 replicate, time resolved controls, part of time series GSM578581 GSM578582 JAK-STAT GSE23591e L1236 lymphoma derived cell line treated with 40 ng/ml IL-13 activation 3 h 1 replicate, time resolved controls, part of time series GSM578583 GSM578584 JAK-STAT GSE23591f L1236 lymphoma derived cell line treated with 40 ng/ml IL-13 activation 4 h 1 replicate, time resolved controls, part of time series GSM578585 GSM578586 JAK-STAT GSE23591g L1236 lymphoma derived cell line treated with 40 ng/ml IL-13 activation 6 h 1 replicate, time resolved controls, part of time series GSM578587 GSM578588 JAK-STAT GSE23591h MedB1 lymphoma derived cell line treated with 20 ng/ml IL-13 activation 0.5 h 1 replicate, time resolved controls, part of time series GSM578595 GSM578596 JAK-STAT GSE23591i MedB1 lymphoma derived cell line treated with 20 ng/ml IL-13 activation 1 h 1 replicate, time resolved controls, part of time series GSM578597 GSM578598 JAK-STAT GSE23591j MedB1 lymphoma derived cell line treated with 20 ng/ml IL-13 activation 1.5 h 1 replicate, time resolved controls, part of time series GSM578599 GSM578600 JAK-STAT GSE23591k MedB1 lymphoma derived cell line treated with 20 ng/ml IL-13 activation 2 h 1 replicate, time resolved controls, part of time series GSM578601 GSM578602 JAK-STAT GSE23591l MedB1 lymphoma derived cell line treated with 20 ng/ml IL-13 activation 3 h 1 replicate, time resolved controls, part of time series GSM578603 GSM578604 JAK-STAT GSE23591m MedB1 lymphoma derived cell line treated with 20 ng/ml IL-13 activation 4 h 1 replicate, time resolved controls, part of time series GSM578605 GSM578606 JAK-STAT GSE23591n MedB1 lymphoma derived cell line treated with 20 ng/ml IL-13 activation 6 h 1 replicate, time resolved controls, part of time series GSM578607 GSM578608 JAK-STAT GSE24403a dermal fibroblasts treated with 50 nM IL-13 activation 2 h 3 replicates control, 1 replicate treatment, part of time series GSM601439,GSM601440,GSM601441 GSM601442 JAK-STAT GSE24403b dermal fibroblasts treated with 50 nM IL-13 activation 4 h 3 replicates control, 1 replicate treatment, part of time series GSM601439,GSM601440,GSM601441 GSM601443 JAK-STAT GSE24409a dermal fibroblasts treated with 50 nM IL-4 activation 2 h 3 replicates control, 1 replicate treatment, part of time series GSM601484,GSM601485,GSM601486 GSM601487 JAK-STAT GSE24409b dermal fibroblasts treated with 50 nM IL-4 activation 4 h 3 replicates control, 1 replicate treatment, part of time series GSM601484,GSM601485,GSM601486 GSM601488 JAK-STAT GSE26949 peripheral blood EPCs/CACs treated with IFNa activation 6 h 6 replicates each GSM663476,GSM663477,GSM663478,GSM663479,GSM663480,GSM663481 GSM663482,GSM663483,GSM663484,GSM663485,GSM663486,GSM663487 JAK-STAT GSE26951 bone marrow EPCs treated with IFNa activation 6 h 5 replicates each GSM663500,GSM663501,GSM663502,GSM663503,GSM663504 GSM663505,GSM663506,GSM663507,GSM663508,GSM663509 JAK-STAT GSE31193 primary hepatocytes treated with 10 U/ml IFN-a activation 6 h 3 replicates GSM773317,GSM773318,GSM773319 GSM773323,GSM773324,GSM773325 JAK-STAT GSE31264 primary hepatocytes treated with 10 U/ml IFN-a activation 6 h 1 replicate GSM774851 GSM774852 JAK-STAT GSE3183 A549 (Human bronchial cell line) treated with IL-13 activation 4 h 3 replicates each GSM47468,GSM47462,GSM47472 GSM47461,GSM47464,GSM47473 JAK-STAT GSE33264a Calu-3 cells treated with 1000 U/ml IFNa activation 3 h 3 replicates each, part of time series with 2 treatment conditions GSM823062,GSM823063,GSM823064 GSM823038,GSM823039,GSM823040 JAK-STAT GSE33264b Calu-3 cells treated with 1000 U/ml IFNa activation 6 h 3 replicates each, part of time series with 2 treatment conditions GSM823065,GSM823066,GSM823067 GSM823041,GSM823042,GSM823043 JAK-STAT GSE33264c Calu-3 cells treated with 500 U/ml IFNg activation 3 h 3 replicates each, part of time series with 2 treatment conditions GSM823074,GSM823075,GSM823076 GSM823050,GSM823051,GSM823052 JAK-STAT GSE33264d Calu-3 cells treated with 500 U/ml IFNg activation 6 h 3 replicates each, part of time series with 2 treatment conditions GSM823077,GSM823078,GSM823079 GSM823053,GSM823054,GSM823055 JAK-STAT GSE3920a HUVECs treated with IFNa activation 5 h 5 replicates GSM89636,GSM89639,GSM89642,GSM89643,GSM89644 GSM89637,GSM89640,GSM89645,GSM89646,GSM89647 JAK-STAT GSE3920b HUVECs treated with IFNb activation 5 h 2 replicates GSM89636,GSM89639 GSM89638,GSM89641 JAK-STAT GSE3920c HUVECs treated with IFNg activation 5 h 3 replicates GSM89636,GSM89639,GSM89642 GSM89648,GSM89649,GSM89650 JAK-STAT GSE3920d fibroblasts treated with IFNa activation 5 h 3 replicates GSM89654,GSM89655,GSM89656 GSM89651,GSM89652,GSM89653 JAK-STAT GSE3920e fibroblasts treated with IFNg activation 5 h 2 replicates GSM89654,GSM89655 GSM89657,GSM89658 JAK-STAT GSE440 Foreskin keratinocytes treated with IFN-gamma (respective time control) activation 1 h 2 Controls existent on the web page only 1 in the whole download script just taken that one GSM6709 GSM7765 JAK-STAT GSE4885a HepG2 hepatocellular carcinoma cells treated with IL-6 activation 1 h 2 replicates, part of time series GSM109801,GSM109802 GSM109803,GSM109804 JAK-STAT GSE4885b HepG2 hepatocellular carcinoma cells treated with IL-6 activation 4 h 2 replicates, part of time series GSM109801,GSM109802 GSM109805,GSM109806 JAK-STAT GSE5542a A549 cell line treated with 500U Infergen (Interferon type 1) activation 6 h 4 replicates GSM128888,GSM128893,GSM128902,GSM128911 GSM128884,GSM128890,GSM128899,GSM128908 JAK-STAT GSE5542b A549 cell line treated with 500U IFN-g1b activation 6 h 4 replicates GSM128888,GSM128893,GSM128902,GSM128911 GSM128885,GSM128891,GSM128900,GSM128909 JAK-STAT GSE8059 NK (Primary Natural Killer cells) treated with IL-2 activation 2 h GSM198942 GSM198943 JAK-STAT GSE8515 human monocyte-derived macrophages treated with IL-6 activation 4 h 5 replicates each GSM211500,GSM211501,GSM211502,GSM211503,GSM211504 GSM211510,GSM211511,GSM211512,GSM211513,GSM211514 JAK-STAT GSE8685a Sez-4 cell line treated with 200U IL-2 activation 4 h 3 replicates, different IL treatments, after 16h IL2 starvation GSM215347,GSM215348,GSM215349 GSM215350,GSM215351,GSM215352 JAK-STAT GSE8685b Sez-4 cell line treated with 20ng/ml IL-15 activation 4 h 3 replicates, different IL treatments, after 16h IL2 starvation GSM215347,GSM215348,GSM215349 GSM215353,GSM215354,GSM215355 JAK-STAT GSE8685c Sez-4 cell line treated with 100ng/ml IL-21 activation 4 h 3 replicates, different IL treatments, after 16h IL2 starvation GSM215347,GSM215348,GSM215349 GSM215356,GSM215357,GSM215358 JAK-STAT GSE8687 Sez-4 starved of IL-2 and activated with IL-2 activation 4 h after stimulation (16 h IL-2 pre-starvation) GSM215362,GSM215363,GSM215361 GSM215365,GSM215366,GSM215364 JAK-STAT GSE9481 side population of ovarian cancer treated with 1000 U/ml IFNa activation 5 h 2 replicates GSM240637,GSM240638 GSM240639,GSM240640 MAPK GSE10088a SkMel-28 cells treated with PD0325901, MEK inhibitor inhibition 2 h 1 replicate each, mainly influencing MAPKs GSM254963 GSM254964 MAPK GSE10088b SkMel-28 cells treated with PD0325901, MEK inhibitor inhibition 8 h 1 replicate each, mainly influencing MAPKs GSM254963 GSM254965 MAPK GSE12764 MCF10A cells transfected with MEK1 activation 24 h 6 replicates each, mostly activates MAPKs GSM320243,GSM320244,GSM320245,GSM320246,GSM320247,GSM320248 GSM320254,GSM320255,GSM320256,GSM320257,GSM320258,GSM320259 MAPK GSE14934b HEK-HT (kidney) Ras (G12V,T35S) activation mutants activation not specified mutants said to be mostly activating Raf GSM373089,GSM373094,GSM373099,GSM373104,GSM373109 GSM373091,GSM373096,GSM373101,GSM373106,GSM373111 MAPK GSE17939 HUVECs transfected with constitutive active MEK5D activation 40 h 3 replicates each, mainly activating MAPKs GSM448023,GSM448025,GSM448043 GSM448029,GSM448041,GSM448047 MAPK GSE3542b MCF-7 (breast cancer cells) co-transfected with constituitively active MEK activation not specified GSM81189,GSM81190,GSM81191 GSM81198,GSM81199,GSM81200 MAPK GSE3542c MCF-7 (breast cancer cells) co-transfected with constituitively active Raf activation not specified GSM81189,GSM81190,GSM81191 GSM81204,GSM81205,GSM81206 MAPK GSE6521a MCF-7 breast cancer cells Treatment with U0126 (MEK inhibitor) inhibition 1.5 h no stimulation GSM149913 GSM149928 MAPK+PI3K GSE10778a human umbilical vein endothelial cells (HUVEC) Treatment with EGF activation 0.5 h time series 30 min, 1 h, 2.5 h 6 h / same with VEGF GSM272113 GSM272118 MAPK+PI3K GSE10778b human umbilical vein endothelial cells (HUVEC) Treatment with EGF activation 1 h time series 30 min, 1 h, 2.5 h 6 h / same with VEGF GSM272113 GSM272119 MAPK+PI3K GSE10778c human umbilical vein endothelial cells (HUVEC) Treatment with EGF activation 2.5 h time series 30 min, 1 h, 2.5 h 6 h / same with VEGF GSM272113 GSM272120 MAPK+PI3K GSE11729a H1299 human non-small cell lung cancer cells Treatment with EGF activation 0.5 h time series: 30 min, 1, 2, 4, 6 and 10 h GSM297647 GSM297648 MAPK+PI3K GSE11729b H1299 human non-small cell lung cancer cells Treatment with EGF activation 1 h time series: 30 min, 1, 2, 4, 6 and 10 h GSM297647 GSM297649 MAPK+PI3K GSE11729c H1299 human non-small cell lung cancer cells Treatment with EGF activation 2 h time series: 30 min, 1, 2, 4, 6 and 10 h GSM297647 GSM297650 MAPK+PI3K GSE11729d H1299 human non-small cell lung cancer cells Treatment with EGF activation 4 h time series: 30 min, 1, 2, 4, 6 and 10 h GSM297647 GSM297651 MAPK+PI3K GSE11729e H1299 human non-small cell lung cancer cells Treatment with EGF activation 6 h time series: 30 min, 1, 2, 4, 6 and 10 h GSM297647 GSM297652 MAPK+PI3K GSE12764b MCF10A cells transfected with HRAS(G12V) activation 24 h 3 replicates each, probably activating PI3K and MAPKs GSM320243,GSM320244,GSM320245,GSM320246,GSM320247,GSM320248 GSM320249,GSM320250,GSM320251,GSM320252,GSM320253 MAPK+PI3K GSE13009a MCF7 human breast cancer cells Treatment with EGF activation 0.5 h time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h GSM325937 GSM325944,GSM325945 MAPK+PI3K GSE13009b MCF7 human breast cancer cells Treatment with EGF activation 1 h time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h GSM325937 GSM325948,GSM325949 MAPK+PI3K GSE13009c MCF7 human breast cancer cells Treatment with EGF activation 2 h time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h GSM325937 GSM325952,GSM325953 MAPK+PI3K GSE13009d MCF7 human breast cancer cells Treatment with EGF activation 4 h time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h GSM325937 GSM325956,GSM325957 MAPK+PI3K GSE13009e MCF7 human breast cancer cells Treatment with HRG activation 0.5 h time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h GSM325937 GSM325978,GSM325979 MAPK+PI3K GSE13009f MCF7 human breast cancer cells Treatment with HRG activation 1 h time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h GSM325937 GSM325982,GSM325983 MAPK+PI3K GSE13009g MCF7 human breast cancer cells Treatment with HRG activation 2 h time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h GSM325937 GSM325986,GSM325987 MAPK+PI3K GSE13009h MCF7 human breast cancer cells Treatment with HRG activation 4 h time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h GSM325937 GSM325990,GSM325991 MAPK+PI3K GSE13009i MCF7 human breast cancer cells Treatment with EGF activation 6 h time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h GSM325937 GSM325958,GSM325959 MAPK+PI3K GSE13009j MCF7 human breast cancer cells Treatment with HRG activation 6 h time series: 10,15,20,30,45,60,90 min, 2, 3, 4, 6...72 h GSM325937 GSM325992,GSM325993 MAPK+PI3K GSE13168a airway smooth muscle cells treated with EGF activation 8 h 1 replicate each, contain control vector, 4 donors GSM332913 GSM332921 MAPK+PI3K GSE13168b airway smooth muscle cells treated with EGF activation 8 h 1 replicate each, contain control vector, 4 donors GSM332914 GSM332922 MAPK+PI3K GSE13168c airway smooth muscle cells treated with EGF activation 8 h 1 replicate each, contain control vector, 4 donors GSM332915 GSM332923 MAPK+PI3K GSE13168d airway smooth muscle cells treated with EGF activation 8 h 1 replicate each, contain control vector, 4 donors GSM332916 GSM332924 MAPK+PI3K GSE14256a Human foreskin fibroblasts (AG01518) Treatment with platelet-derived growth factor-BB (PDGF-BB) activation 1 h GSM356969,GSM356970 GSM356966,GSM356973 MAPK+PI3K GSE14256b Human foreskin fibroblasts (AG01518) Treatment with bFGF (basic fibroblast growth factor) activation 1 h GSM356969,GSM356970 GSM356968,GSM356971 MAPK+PI3K GSE14934a HEK-HT (kidney) Ras (G12V) activation mutants activation not specified GSM373089,GSM373094,GSM373099,GSM373104,GSM373109 GSM373090,GSM373095,GSM373100,GSM373105,GSM373110 MAPK+PI3K GSE20277 HeLa cells treated with EGF activation 0.66 h 3 replicates each GSM508433,GSM508434,GSM508435 GSM507245,GSM507246,GSM507247 MAPK+PI3K GSE33710 WI-38 cells RASv12 overexpression activation not indicated 3 replicates each GSM833183,GSM833184,GSM833185 GSM833186,GSM833187,GSM833188 MAPK+PI3K GSE3542a MCF-7 (breast cancer cells) co-transfected with constituitively active erbB-2 activation not specified GSM81189,GSM81190,GSM81191 GSM81195,GSM81196,GSM81197 MAPK+PI3K GSE3542d MCF-7 (breast cancer cells) co-transfected with ligand-inducible EGFR activation not specified GSM81189,GSM81190,GSM81191 GSM81201,GSM81202,GSM81203 MAPK+PI3K GSE6462a MCF-7 (human breast cancer) treatment with EGF (10nm) activation 0.75 h GSM148516 GSM148543 MAPK+PI3K GSE6462b MCF-7 (human breast cancer) treatment with EGF (10nm) activation 1.5 h GSM148516 GSM148544 MAPK+PI3K GSE6462c MCF-7 (human breast cancer) treatment with 10 nm HRG= heregulin Erb3/4 Ligand activation 0.75 h GSM148517 GSM148570 MAPK+PI3K GSE6462d MCF-7 (human breast cancer) treatment with 10 nm HRG= heregulin Erb3/4 Ligand activation 1.5 h GSM148517 GSM148572 MAPK+PI3K GSE6521d MCF-7 breast cancer cells Treatment with HRG (heregulin ErbB3 Ligand) activation 0.75 h GSM149913 GSM149919 MAPK+PI3K GSE6521e MCF-7 breast cancer cells Treatment with HRG (heregulin ErbB3 Ligand) activation 1.5 h GSM149913 GSM149921 MAPK+PI3K GSE6783a HELA (Human cervical carcinoma cell line) EGF treatment after 24 h serum starvation (Control 0 h) activation 0.33 h GSM156764 GSM156765 MAPK+PI3K GSE6783b HELA (Human cervical carcinoma cell line) EGF treatment after 24 h serum starvation (Control 0 h) activation 1 h GSM156764 GSM156767 MAPK+PI3K GSE6783c HELA (Human cervical carcinoma cell line) EGF treatment after 24 h serum starvation (Control 0 h) activation 2 h GSM156764 GSM156768 MAPK+PI3K GSE6783d HELA (Human cervical carcinoma cell line) EGF treatment after 24 h serum starvation (Control 0 h) activation 4 h GSM156764 GSM156769 MAPK+PI3K GSE6784a MCF-10A (mammary epithelial cell line) EGF treatment after 24 h serum starvation (Control 0 h) activation 0.33 h GSM156771 GSM156772 MAPK+PI3K GSE6784b MCF-10A (mammary epithelial cell line) EGF treatment after 24 h serum starvation (Control 0 h) activation 1 h GSM156771 GSM156774 MAPK+PI3K GSE6784c MCF-10A (mammary epithelial cell line) EGF treatment after 24 h serum starvation (Control 0 h) activation 2 h GSM156771 GSM156775 MAPK+PI3K GSE6784d MCF-10A (mammary epithelial cell line) EGF treatment after 24 h serum starvation (Control 0 h) activation 4 h GSM156771 GSM156776 MAPK+PI3K GSE7403a SH-SY5Y (Neuroblastoma cells) PDGF treatment with 60 min prior DMSO treatment activation 0.5 h GSM178575,GSM178576 GSM178569,GSM178570 MAPK+PI3K GSE7403c SH-SY5Y (Neuroblastoma cells) PDGF treatment with 60 min prior DMSO treatment activation 1 h GSM178583 GSM178577,GSM178578 MAPK+PI3K GSE7403e SH-SY5Y (Neuroblastoma cells) PDGF treatment with 60 min prior DMSO treatment activation 2 h GSM178590,GSM178591 GSM178584,GSM178585 MAPK+PI3K GSE7403g SH-SY5Y (Neuroblastoma cells) PDGF treatment with 60 min prior DMSO treatment activation 4 h GSM178606,GSM178607 GSM178600,GSM178601 MAPK+PI3K GSE8471 MCF7 HRG stimulated (ErbB Ligand) activation 2 h after stimulation GSM210180 GSM210181 TLR GSE10316a monocyte derived dendritic cells treated with 1 µg/ml LPS activation 4 h 1 replicate each GSM260689 GSM260690 TLR GSE10316b monocyte derived dendritic cells treated with 50 µg/ml polyI:C activation 4 h 1 replicate each GSM260689 GSM260693 TLR GSE14000a primary blood cells treated with LPS activation 4 h 1 replicate each, 4 donors GSM349874 GSM349876 TLR GSE14000b primary blood cells treated with LPS activation 4 h 1 replicate each, 4 donors GSM351530 GSM351532 TLR GSE14000c primary blood cells treated with LPS activation 4 h 1 replicate each, 4 donors GSM351537 GSM351539 TLR GSE14000d primary blood cells treated with LPS activation 4 h 1 replicate each, 4 donors GSM351622 GSM351638 TLR GSE14419a primary macrophages treated with zymosan A activation 3 h 1 replicate each, 4 donors GSM360139 GSM360141 TLR GSE14419b primary macrophages treated with zymosan A activation 3 h 1 replicate each, 4 donors GSM360143 GSM360145 TLR GSE14419c primary macrophages treated with zymosan A activation 3 h 1 replicate each, 4 donors GSM360182 GSM360184 TLR GSE14419d primary macrophages treated with zymosan A activation 3 h 1 replicate each, 4 donors GSM360186 GSM360188 TLR GSE1541aNFkB A549 (Alveolar Epithelial Cells line) treated with LPS activation 1 h GSM26477,GSM26478 GSM26481,GSM26482 TLR GSE1541bNFkB A549 (Alveolar Epithelial Cells line) treated with LPS activation 4 h GSM26479,GSM26480 GSM26483,GSM26484 TLR GSE16193 THP1 monocytic cell line treated with 1 µg/ml LPS activation 1 h 5 replicates each GSM406482,GSM406483,GSM406484,GSM406485,GSM406486 GSM406497,GSM406498,GSM406499,GSM406500,GSM406501 TLR GSE19315 THP1 monocytic cell line treated with LPS activation 6 h 3 replicates each GSM479983,GSM479984,GSM479985 GSM479986,GSM479987,GSM479988 TLR GSE19627 THP1 monocytes treated with LPS activation 4 h 3 replicates each GSM489343,GSM489344,GSM489345 GSM489337,GSM489338,GSM489339 TLR GSE19738a whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492850 GSM492917 TLR GSE19738a2 whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492876 GSM492943 TLR GSE19738a3 whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492877 GSM492944 TLR GSE19738a4 whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492878 GSM492945 TLR GSE19738a6 whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492880 GSM492947 TLR GSE19738a7 whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492881 GSM492948 TLR GSE19738a8 whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492882 GSM492949 TLR GSE19738a9 whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492883 GSM492950 TLR GSE19738b whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492851 GSM492918 TLR GSE19738c whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492852 GSM492919 TLR GSE19738d whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492853 GSM492920 TLR GSE19738e whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492854 GSM492921 TLR GSE19738f whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492855 GSM492922 TLR GSE19738g whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492856 GSM492923 TLR GSE19738h whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492857 GSM492924 TLR GSE19738i whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492858 GSM492925 TLR GSE19738j whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492859 GSM492926 TLR GSE19738k whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492860 GSM492927 TLR GSE19738l whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492861 GSM492928 TLR GSE19738m whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492862 GSM492929 TLR GSE19738n whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492863 GSM492930 TLR GSE19738o whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492864 GSM492931 TLR GSE19738p whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492865 GSM492932 TLR GSE19738q whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492866 GSM492933 TLR GSE19738r whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492867 GSM492934 TLR GSE19738s whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492868 GSM492935 TLR GSE19738t whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492869 GSM492936 TLR GSE19738v whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492871 GSM492938 TLR GSE19738w whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492872 GSM492939 TLR GSE19738x whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492873 GSM492940 TLR GSE19738y whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492874 GSM492941 TLR GSE19738z whole blood cells treated with LPS activation 5-6 h 1 replicate each, 34 individuals GSM492875 GSM492942 TLR GSE20114a primary blood cells treated with LPS activation 4 h 1 replicate each, 4 donors GSM502612 GSM502620 TLR GSE20114b primary blood cells treated with LPS activation 4 h 1 replicate each, 4 donors GSM502613 GSM502621 TLR GSE20114c primary blood cells treated with LPS activation 4 h 1 replicate each, 4 donors GSM502614 GSM502622 TLR GSE20114d primary blood cells treated with LPS activation 4 h 1 replicate each, 4 donors GSM502615 GSM502623 TLR GSE22248a PBMCs treated with LPS activation 4 h 1 replicates each, 4 individuals GSM553736 GSM553737 TLR GSE22248b PBMCs treated with LPS activation 4 h 1 replicates each, 4 individuals GSM553739 GSM553740 TLR GSE22248c PBMCs treated with LPS activation 4 h 1 replicates each, 4 individuals GSM553742 GSM553743 TLR GSE22248d PBMCs treated with LPS activation 4 h 1 replicates each, 4 individuals GSM553745 GSM553746 TLR GSE23371 dendritic cells treated with LPS activation 6 h 3 technical replicates each GSM573357,GSM573358,GSM573359 GSM573360,GSM573361,GSM573362 TLR GSE2396 human gammadelta T cells treated with LPS activation 4 h 4 cell cultures pooled GSM45116 GSM45117 TLR GSE24897 macrophages treated with PG-LPS activation 2 h 3 replicates each GSM612262,GSM612263,GSM612264 GSM612268,GSM612269,GSM612270 TLR GSE25155a HEK TLR2 transfected treated with 10µg/ml H. pylori LPS activation 2 h 2 replicates each, part of time series GSM618017,GSM618018 GSM618019,GSM618020 TLR GSE2706 Monocyte derived dendritic cells treated with LPS activation 2 h 3 replicates GSM52346,GSM52353,GSM52360 GSM52340,GSM52347,GSM52354 TLR GSE29700 BL-2 burkitt lymphoma cell line treated with LPS activation 6 h 3 replicates each GSM736728,GSM736729,GSM736730 GSM736731,GSM736732,GSM736733 TLR GSE3037a primary periphal blood neutrophils treated with LPS activation 1 h 1 replicate each, 8 individuals GSM66867 GSM66884 TLR GSE3037b primary periphal blood neutrophils treated with LPS activation 1 h 1 replicate each, 8 individuals GSM66868 GSM66884 TLR GSE3037c primary periphal blood neutrophils treated with LPS activation 1 h 1 replicate each, 8 individuals GSM66869 GSM66885 TLR GSE3037d primary periphal blood neutrophils treated with LPS activation 1 h 1 replicate each, 8 individuals GSM66870 GSM66886 TLR GSE3037e primary periphal blood neutrophils treated with LPS activation 1 h 1 replicate each, 8 individuals GSM66871 GSM66887 TLR GSE3037f primary periphal blood neutrophils treated with LPS activation 1 h 1 replicate each, 8 individuals GSM66872 GSM66888 TLR GSE3037g primary periphal blood neutrophils treated with LPS activation 1 h 1 replicate each, 8 individuals GSM66873 GSM66889 TLR GSE3037h primary periphal blood neutrophils treated with LPS activation 1 h 1 replicate each, 8 individuals GSM66874 GSM66890 TLR GSE3140a mononuclear cells from adult peripheral blood treated with 5 µg/ml LPS activation 4 h 3 replicates each, time might not be exact but probably 4h or 2h GSM70121,GSM70122,GSM70123 GSM70124,GSM71079,GSM71080 TLR GSE3140b mononuclear cells from cord blood treated with 5 µg/ml LPS activation 4 h 3 replicates each, time might not be exact but probably 4h or 2h GSM71081,GSM71082,GSM71083 GSM71084,GSM71085,GSM71086 TLR GSE32390aNFkB fibroblasts treated with poly I:C activation 4 h 1 replicate each, 3 individuals GSM801677 GSM801667 TLR GSE32390bNFkB fibroblasts treated with poly I:C activation 4 h 1 replicate each, 3 individuals GSM801680 GSM801684 TLR GSE32390cNFkB fibroblasts treated with poly I:C activation 4 h 1 replicate each, 3 individuals GSM801681 GSM801674 TLR GSE32390dNFkB PBMCs treated with 10 ng/ml LPS activation 2 h 1 replicate each GSM801688 GSM801685 TLR GSE32390e PBMCs treated with 3 µg/ml R848 activation 2 h 1 replicate each, R848 is a relative specific TLR7/8 agonist GSM801688 GSM801685 TLR GSE3491a GENDER: MALE TISSUE: WHOLE BLOOD LPS RESPONSE: HIGH treated with LPS 10 NG/ML activation 4 h three patients with high LPS response rate GSM78606 GSM78607 TLR GSE3491b GENDER: MALE TISSUE: WHOLE BLOOD LPS RESPONSE: HIGH treated with LPS 10 NG/ML activation 4 h three patients with high LPS response rate GSM79057 GSM79058 TLR GSE3491c GENDER: FEMALE TISSUE: WHOLE BLOOD LPS RESPONSE: HIGH treated with LPS 10 NG/ML activation 4 h three patients with high LPS response rate GSM79064 GSM79067 TLR GSE3720a expanded peripheral blood Vd1 gd T lymphocytes treated with LPS 10 mg/mL activation 4 h 3 week culture with Vd1 mab 0.1mg/mL, pan gd mAb 0.1 mg/mL, and IL-15 10ng/mL GSM85804,GSM85805 GSM85806,GSM85807 TLR GSE3720b expanded peripheral blood Vd2 gd T lymphocytes treated with LPS 10 mg/mL activation 4 h 3 week culture with Vd1 mab 0.1mg/mL, pan gd mAb 0.1 mg/mL, and IL-15 10ng/mL GSM85810,GSM85811 GSM85812,GSM85813 TLR GSE3982 macrophages derived from monocytes treated with LPS activation 4 h 2 replicates each GSM90838,GSM90839 GSM90840,GSM90841 TLR GSE4748 Monocyte derived dendritic cells treated with LPS 0.5 g/ml 3 h GSM107453,GSM107458 GSM107455,GSM107460 TLR GSE510316 monocyte-derived dendritic cells treated with LPS 1 g/ml 4 h immature cells GSM260689 GSM260690 TLR GSE518047a H929 (Multiple Myeloma Cell Line) transfected with NIK undefined overexpression directly above NFkB GSM451261,GSM451264,GSM451267 GSM451262,GSM451265,GSM451268 TLR GSE518047b H929 (Multiple Myeloma Cell Line) transfected with IKKB undefined overexpression directly above NFkB GSM451261,GSM451264,GSM451267 GSM451263,GSM451266,GSM451269 TLR GSE518047c SACHI (Multiple Myeloma Cell Line) transfected with NIK undefined overexpression directly above NFkB GSM451270,GSM451273,GSM451276 GSM451271,GSM451274,GSM451277 TLR GSE518047d SACHI (Multiple Myeloma Cell Line) transfected with IKKB undefined overexpression directly above NFkB GSM451270,GSM451273,GSM451276 GSM451272,GSM451275,GSM451278 TLR GSE53982a Human CD16+, CCR3- peripheral blood neutrophils treated with LPS 100 ng/ml 1 h GSM90843,GSM90844 GSM90847 TLR GSE53982b Macrophages differentiated from isolated CD14+ monocytes in the presence of GM-CSF treated with LPS 100 ng/ml 4 h GSM90838,GSM90839 GSM90840,GSM90841 TLR GSE5504a human peripheral blood derived monocytes treated with LPS activation 2 h GSM126988,GSM126993 GSM126994,GSM126995 TLR GSE5504b human peripheral blood derived monocytes treated with LPS activation 4 h GSM126988,GSM126993 GSM126996,GSM126997 TLR GSE5883 HMVEC-L (Microvascular endothelial cells, lung) treated with LPS 10 ng activation 4 h 4 replicates each GSM114564,GSM114565,GSM114566,GSM114567 GSM114552,GSM114553,GSM114554,GSM114555 TLR GSE7850a Retinal endothelial cell treated with LPS 10 100 ng/mL activation 4 h three different patients 2 different tissues GSM190517,GSM190518 GSM190519,GSM190520 TLR GSE7850b Choroidal endothelial cell treated with LPS 10 100 ng/mL activation 4 h three different patients 2 different tissues GSM190521,GSM190522 GSM190523,GSM190524 TLR GSE7850c Retinal endothelial cell treated with LPS 10 100 ng/mL activation 4 h three different patients 2 different tissues GSM190525,GSM190526 GSM190527,GSM190528 TLR GSE7850d Choroidal endothelial cell treated with LPS 10 100 ng/mL activation 4 h three different patients 2 different tissues GSM190529,GSM190530 GSM190531,GSM190532 TLR GSE7850e Retinal endothelial cell treated with LPS 10 100 ng/mL activation 4 h three different patients 2 different tissues GSM190533,GSM190534 GSM190535,GSM190536 TLR GSE7850f Choroidal endothelial cell treated with LPS 10 100 ng/mL activation 4 h three different patients 2 different tissues GSM190537,GSM190538 GSM190539,GSM190540 TLR GSE8190a epithelial cells treated with LPS activation 4 h 2 replicates each, 14 individuals GSM202420,GSM202421 GSM202416,GSM202417 TLR GSE8190c epithelial cells treated with LPS activation 4 h 2 replicates each, 14 individuals GSM202430,GSM202431 GSM202432,GSM202433 TLR GSE8190d epithelial cells treated with LPS activation 4 h 2 replicates each, 14 individuals GSM202440,GSM202441 GSM202436,GSM202437 TLR GSE8190e epithelial cells treated with LPS activation 4 h 2 replicates each, 14 individuals GSM202452,GSM202453 GSM202448,GSM202449 TLR GSE8190f epithelial cells treated with LPS activation 4 h 2 replicates each, 14 individuals GSM202476,GSM202477 GSM202472,GSM202473 TLR GSE8190g epithelial cells treated with LPS activation 4 h 2 replicates each, 14 individuals GSM202486,GSM202487 GSM202482,GSM202483 TLR GSE8190h epithelial cells treated with LPS activation 4 h 2 replicates each, 14 individuals GSM202510,GSM202511 GSM202506,GSM202507 TLR GSE8190i epithelial cells treated with LPS activation 4 h 2 replicates each, 14 individuals GSM202516,GSM202517 GSM202512,GSM202513 TLR GSE8190k epithelial cells treated with LPS activation 4 h 2 replicates each, 14 individuals GSM202591,GSM202662 GSM202589,GSM202660 TLR GSE8190l epithelial cells treated with LPS activation 4 h 2 replicates each, 14 individuals GSM202594,GSM202665 GSM202592,GSM202663 TLR GSE8608 monocyte-derived macrophages of 13 male healthy subjects treated with LPS 10ng/ml activation 4 h GSM213500 GSM213511 TLR GSE9916 THP-1 cell line treated with 1 µg/ml LPS activation 4 h 3 replicates each GSM250931,GSM250932,GSM250933 GSM250940,GSM250941,GSM250942 TLR GSE9988a Human monocytes (donor 1) treated with LPS activation 2 h 10 anonymous donors in this set GSM252485 GSM252451 TLR GSE9988b Human monocytes (donor 2) treated with LPS activation 2 h 10 anonymous donors in this set GSM252481 GSM252448 TLR GSE9988c Human monocytes (donor 3) treated with LPS activation 2 h 10 anonymous donors in this set GSM252480 GSM252447 TLR GSE9988d Human monocytes (donor 4) treated with LPS activation 2 h 10 anonymous donors in this set GSM252479 GSM252444 TLR GSE9988e Human monocytes (donor 5) treated with LPS activation 2 h 10 anonymous donors in this set GSM252482 GSM252450 TLR GSE9988f Human monocytes (donor 6) treated with LPS activation 2 h 10 anonymous donors in this set GSM252478 GSM252452 TLR GSE9988g Human monocytes (donor 7) treated with LPS activation 2 h 10 anonymous donors in this set GSM252483 GSM252443 TLR GSE9988h Human monocytes (donor 8) treated with LPS activation 2 h 10 anonymous donors in this set GSM252477 GSM252454 TLR GSE9988i Human monocytes (donor 9) treated with LPS activation 2 h 10 anonymous donors in this set GSM252484 GSM252449 TLR GSE9988j Human monocytes (donor 11) treated with LPS activation 2 h 10 anonymous donors in this set GSM252476 GSM252453 Notch GSE104260 T-Acute Lymphoblastic Leukemia cell line TALL-1 Gamma secretase inhibitor compund E 1µM inhibition 24h two replicates GSM2793819,GSM2793820 GSM2793821,GSM2793822 Notch GSE115690a T-All cell line with Notch activating mutations TALL-1 inhibition 16h three replicate, 2 cell lines taken GSM3187737,GSM3187738,GSM3187739 GSM3187740,GSM3187741,GSM3187742 Notch GSE115690b T-All cell line with Notch activating mutations RPMI.8402 inhibition 16h three replicate, 2 cell lines taken GSM3187755,GSM3187756,GSM3187757 GSM3187758,GSM3187759,GSM3187760 Notch GSE12355 EREB2-5 B cell line transfected with Notch1 intracellular domain activation 8 h 3 replicates each GSM310330,GSM310331,GSM310332 GSM310333,GSM310334,GSM310335 Notch GSE125349 human MCL cell line Mino (Notch1 mutation causing prolonged activation upon stimulation) inhibition 48h no replicate, compared is DLL4 stimulated (Notch1 activated) vs DLL4 + Notch1 antibody GSM3569343 GSM3569345 Notch GSE16477a embryonal neuroblast cell line IMR32 inducible Notch3 via dox activation 4h two replicates, two clones combined GSM414091,GSM414100 GSM414092,GSM414101 Notch GSE16477b embryonal neuroblast cell line IMR32 inducible Notch3 via dox activation 8h two replicates, two clones combined GSM414091,GSM414100 GSM414093,GSM414102 Notch GSE29544a CUTLL1 cells treated with washout of GSI inhibitor activation 2 h 3 replicates each, treatment after 3 days treatment with GSI, GSI= gamma secretase inhibitor GSM731503,GSM731504,GSM731505 GSM731506,GSM731507,GSM731508 Notch GSE29544b CUTLL1 cells treated with washout of GSI inhibitor activation 4 h 3 replicates each, treatment after 3 days treatment with GSI, GSI= gamma secretase inhibitor GSM731503,GSM731504,GSM731505 GSM731513,GSM731514,GSM731512 Notch GSE29959a human T-ALL cell line ALLSIL inhibition 12h no replicate, 5 cell lines!!! GSM741305 GSM741306 Notch GSE29959b human T-ALL cell line DND41 inhibition 12h no replicate, 5 cell lines!!! GSM741311 GSM741312 Notch GSE29959c human T-ALL cell line HPBALL inhibition 12h no replicate, 5 cell lines!!! GSM741317 GSM741318 Notch GSE29959d human T-ALL cell line KOPTK1 inhibition 12h no replicate, 5 cell lines!!! GSM741323 GSM741324 Notch GSE29959e human T-ALL cell line TALL-1 inhibition 12h no replicate, 5 cell lines!!! GSM741329 GSM741330 Notch GSE30288 gamma-secretase inhibitor MRK-003 10µM inhibition 4h three replicates GSM750722,GSM750727,GSM750733 GSM750730,GSM750728,GSM750725 Notch GSE34602a MCl cell line Rec1 gama secretase inhibitor compound E inhibition 24h two replicates, second sensitive cell line also included GSM851735,GSM851736 GSM851737,GSM851738 Notch GSE34602b MCl cell line SP-49 gama secretase inhibitor compound E inhibition 24h two replicates, second sensitive cell line also included GSM851739,GSM851740 GSM851741,GSM851742 Notch GSE36051a breast cancer cell line MCF7 induction of Notch via Jagged1-FC activation 6h three replicates, control is Jagged1-FC + gamma secretase inhibitor DAPTK GSM879944,GSM879945,GSM879946 GSM879941,GSM879942,GSM879943 Notch GSE36051b breast cancer cell line MDA-MB-231 induction of Notch via Jagged1-FC activation 6h three replicates, control is Jagged1-FC + gamma secretase inhibitor DAPTK GSM879959,GSM879960,GSM879961 GSM879956,GSM879957,GSM879958 Notch GSE36176a A549 cells treated with 2µM GSI RO4929097 inhibition 6 h 4 replicates each, different cell lines, GSI= gamma secretase inhibitor GSM882357,GSM882358,GSM882359,GSM882360 GSM882361,GSM882362,GSM882363,GSM882364 Notch GSE36176b H460 cells treated with 2µM GSI RO4929097 inhibition 6 h 4 replicates each, different cell lines, GSI= gamma secretase inhibitor GSM882373,GSM882374,GSM882375,GSM882376 GSM882377,GSM882378,GSM882379,GSM882380 Notch GSE39223 U87-EV human glioblastoma xenograft inhibition 72h + 4h 3 replicates each GSM958322,GSM958323,GSM958324 GSM958325,GSM958326,GSM958327 Notch GSE45750 Umbilical vein endothelial cells gamma secretase inhibitor DAPT inhibition 48 h 3 replicates each GSM1113592,GSM1113593,GSM1113594 GSM1113595,GSM1113596,GSM1113597 Notch GSE50841 Colon cancer cell line SW480 with BOP1 overexpression inhibition 24h two replicates GSM1231036,GSM1231037 GSM1231054,GSM1231055 Notch GSE82298 Triple negative breast cancer MBA-MB-468 cells inhibition 24h three replicates GSM2188520,GSM2188522,GSM2188523 GSM2188519,GSM2188521,GSM2188525 Notch GSE85986 HUVEC treated with IL1-ß for 4h inhibition 48h three replicates GSM2290151,GSM2290152,GSM2290153 GSM2290157,GSM2290158,GSM2290159 p53 GSE12666a MCF7 cells treated with 10 µM BMH-7, p53 activator activation 6 h 4 replicates each, lead compounds - mechanism of action unknown GSM318069,GSM318070,GSM318071,GSM318072 GSM318045,GSM318046,GSM318047,GSM318048 p53 GSE12666b MCF7 cells treated with 10 µM BMH-9, p53 activator activation 6 h 4 replicates each, lead compounds - mechanism of action unknown GSM318069,GSM318070,GSM318071,GSM318072 GSM318049,GSM318050,GSM318051,GSM318052 p53 GSE12666c MCF7 cells treated with 10 µM BMH-15, p53 activator activation 6 h 4 replicates each, lead compounds - mechanism of action unknown GSM318069,GSM318070,GSM318071,GSM318072 GSM318053,GSM318054,GSM318055,GSM318056 p53 GSE12666d MCF7 cells treated with 10 µM BMH-21, p53 activator activation 6 h 4 replicates each, lead compounds - mechanism of action unknown GSM318069,GSM318070,GSM318071,GSM318072 GSM318057,GSM318058,GSM318059,GSM318060 p53 GSE12666e MCF7 cells treated with 10 µM BMH-22, p53 activator activation 6 h 4 replicates each, lead compounds - mechanism of action unknown GSM318069,GSM318070,GSM318071,GSM318072 GSM318061,GSM318062,GSM318063,GSM318064 p53 GSE12666f MCF7 cells treated with 10 µM BMH-23, p53 activator activation 6 h 4 replicates each, lead compounds - mechanism of action unknown GSM318069,GSM318070,GSM318071,GSM318072 GSM318065,GSM318066,GSM318067,GSM318068 p53 GSE13291 MCF7 cells treated with 1 µM RITA, p53 activator activation 2 h 1 replicate each, RITA inhibits HDM2-p53 interaction GSM335410 GSM335411 p53 GSE2238 HT1080 fibrosarcoma cells treated with doxorubicin activation 6 h 1 replicate each GSM40961 GSM40962 p53 GSE23010 U2OS cells treated with 5 GY X-Ray irradiation activation 4 h 3 replicates each, cells transfected with control sh RNA GSM567732,GSM567740,GSM567748 GSM567733,GSM567741,GSM567749 p53 GSE30240a G361 cells treated with 5 GY X-Ray irradiation activation 3 h 3 replicates each, part of time series, time respective control, 5 different tissues GSM748818,GSM748819,GSM748820 GSM748824,GSM748825,GSM748826 p53 GSE30240b G361 cells treated with 5 GY X-Ray irradiation activation 6 h 3 replicates each, part of time series, time respective control, 5 different tissues GSM748821,GSM748822,GSM748823 GSM748827,GSM748828,GSM748829 p53 GSE30240c HepG2 cells treated with 5 GY X-Ray irradiation activation 3 h 3 replicates each, part of time series, time respective control, 5 different tissues GSM748833,GSM748834,GSM748835 GSM748839,GSM748840,GSM748841 p53 GSE30240d HepG2 cells treated with 5 GY X-Ray irradiation activation 6 h 3 replicates each, part of time series, time respective control, 5 different tissues GSM748836,GSM748837,GSM748838 GSM748842,GSM748843,GSM748844 p53 GSE30240e TK6 cells treated with 5 GY X-Ray irradiation activation 3 h 3 replicates each, part of time series, time respective control, 5 different tissues GSM748848,GSM748849,GSM748850 GSM748854,GSM748855,GSM748856 p53 GSE30240f TK6 cells treated with 5 GY X-Ray irradiation activation 6 h 3 replicates each, part of time series, time respective control, 5 different tissues GSM748851,GSM748852,GSM748853 GSM748857,GSM748858,GSM748859 p53 GSE30240g U2OS cells treated with 5 GY X-Ray irradiation activation 3 h 3 replicates each, part of time series, time respective control, 5 different tissues GSM748863,GSM748864,GSM748865 GSM748869,GSM748870,GSM748871 p53 GSE30240h U2OS cells treated with 5 GY X-Ray irradiation activation 6 h 3 replicates each, part of time series, time respective control, 5 different tissues GSM748866,GSM748867,GSM748868 GSM748872,GSM748873,GSM748874 p53 GSE30240i BJ cells treated with 5 GY X-Ray irradiation activation 3 h 3 replicates each, part of time series, time respective control, 5 different tissues GSM749871,GSM749872,GSM749873 GSM749880,GSM749881,GSM749882 p53 GSE30240j BJ cells treated with 5 GY X-Ray irradiation activation 6 h 3 replicates each, part of time series, time respective control, 5 different tissues GSM749874,GSM749875,GSM749876 GSM749883,GSM749884,GSM749885 p53 GSE32441 HT1080 fibrosarcoma cells treated with 0.25 µg/ml doxorubicin activation 6 h 1 replicate each GSM802712 GSM802717 p53 GSE8939a CS-B wt rescued cells treated with 10 J/m2 UVC irradiation activation 2 h 3 replicates each, 2 arrays per sample GSM226614,GSM226615,GSM226619 GSM226620,GSM226621,GSM226622 p53 GSE8939b CS-B wt rescued cells treated with 10 J/m2 UVC irradiation activation 2 h 3 replicates each, 2 arrays per sample GSM226616,GSM226617,GSM226618 GSM226623,GSM226624,GSM226625 PI3K GSE10086a MDA468 cells treated with PD0325901, MEK inhibitor activation 8 h 1 replicate each, mainly activating PI3K pathway, 12 different cell lines GSM254931 GSM254932 PI3K GSE10086b H1650 cells treated with PD0325901, MEK inhibitor activation 8 h 1 replicate each, mainly activating PI3K pathway, 12 different cell lines GSM254933 GSM254934 PI3K GSE10086c A431 cells treated with PD0325901, MEK inhibitor activation 8 h 1 replicate each, mainly activating PI3K pathway, 12 different cell lines GSM254935 GSM254936 PI3K GSE10086d BT474 cells treated with PD0325901, MEK inhibitor activation 8 h 1 replicate each, mainly activating PI3K pathway, 12 different cell lines GSM254937 GSM254938 PI3K GSE10086e SKBR3 cells treated with PD0325901, MEK inhibitor activation 8 h 1 replicate each, mainly activating PI3K pathway, 12 different cell lines GSM254939 GSM254940 PI3K GSE10086f COLO205 cells treated with PD0325901, MEK inhibitor activation 8 h 1 replicate each, mainly activating PI3K pathway, 12 different cell lines GSM254941 GSM254942 PI3K GSE10086g HT29 cells treated with PD0325901, MEK inhibitor activation 8 h 1 replicate each, mainly activating PI3K pathway, 12 different cell lines GSM254943 GSM254944 PI3K GSE10086h MALME3M cells treated with PD0325901, MEK inhibitor activation 8 h 1 replicate each, mainly activating PI3K pathway, 12 different cell lines GSM254945 GSM254946 PI3K GSE10086i SKMEL1 cells treated with PD0325901, MEK inhibitor activation 8 h 1 replicate each, mainly activating PI3K pathway, 12 different cell lines GSM254947 GSM254948 PI3K GSE10086j SKMEL5 cells treated with PD0325901, MEK inhibitor activation 8 h 1 replicate each, mainly activating PI3K pathway, 12 different cell lines GSM254949 GSM254950 PI3K GSE10086k SKMEL19 cells treated with PD0325901, MEK inhibitor activation 8 h 1 replicate each, mainly activating PI3K pathway, 12 different cell lines GSM254951 GSM254952 PI3K GSE10086l SKMEL28 cells treated with PD0325901, MEK inhibitor activation 8 h 1 replicate each, mainly activating PI3K pathway, 12 different cell lines GSM254953 GSM254954 PI3K GSE14934c HEK-HT (kidney) Ras (G12V,Y40C) activation mutants activation not specified mutants said to be mostly activating PI3K GSM373089,GSM373094,GSM373099,GSM373104,GSM373109 GSM373093,GSM373098,GSM373103,GSM373108,GSM373113 PI3K GSE17785a MCF10A cells PI3K activated mutants activation not indicated 3 replicates each GSM443978,GSM443979,GSM443980 GSM443984,GSM443985,GSM443986 PI3K GSE17785b MCF10A cells treated with GDC-0941. a PI3K inhibitor inhibition 4 h 3 replicates each GSM443978,GSM443979,GSM443980 GSM443981,GSM443982,GSM443983 PI3K GSE26599 HB4a cells treated with rapamycin inhibition not indicated 5 replicates each, rapamycin inhibits mTOR --> inhibition of PI3K pathway GSM654640,GSM654641,GSM654642,GSM654643,GSM654644 GSM654650,GSM654651,GSM654652,GSM654653,GSM654654 PI3K GSE3737 PC3 (prostate cancer cell) treatment with arachidonic acid (AA) should activate PI3K activation 2 h GSM86082 GSM86085,GSM86086 PI3K GSE6521b MCF-7 breast cancer cells Treatment with U0126 (MEK inhibitor) + HRG (heregulin ErbB3 Ligand) activation 0.75 h besides PI3K also all non Raf Ras targets activated GSM149913 GSM149933 PI3K GSE6521c MCF-7 breast cancer cells Treatment with U0126 (MEK inhibitor) + HRG (heregulin ErbB3 Ligand) activation 1.5 h besides PI3K also all non Raf Ras targets activated GSM149913 GSM149935 PI3K GSE7403b SH-SY5Y (Neuroblastoma cells) PDGF treatment with 60 min prior U0126 treatment activation 0.5 h GSM178575,GSM178576 GSM178571,GSM178572 PI3K GSE7403d SH-SY5Y (Neuroblastoma cells) PDGF treatment with 60 min prior U0126 treatment activation 1 h GSM178583 GSM178579,GSM178580 PI3K GSE7403f SH-SY5Y (Neuroblastoma cells) PDGF treatment with 60 min prior U0126 treatment activation 2 h GSM178590,GSM178591 GSM178586,GSM178587 PI3K GSE7403h SH-SY5Y (Neuroblastoma cells) PDGF treatment with 60 min prior U0126 treatment activation 4 h GSM178606,GSM178607 GSM178602,GSM178603 PI3K GSE7562a A431 PTEN hcRNA knockdown activation not specified (until log Phase) GSM183432,GSM183433 GSM183434,GSM183435 PI3K GSE7562b HCC827 PTEN hcRNA knockdown activation not specified (until log Phase) GSM183436,GSM183437 GSM183438,GSM183439 PI3K GSE7562c SKBR3 PTEN hcRNA knockdown activation not specified (until log Phase) GSM183440,GSM183441 GSM183442,GSM183443 PPAR GSE16385a primary monocytes treated with 1mM rosiglitazone, a PPARg agonist activation 4 h 1 replicate each, differently activated macrophages GSM411184 GSM411185 PPAR GSE16385b primary IL4 activated monocytes treated with 1mM rosiglitazone, a PPARg agonist activation 4 h 1 replicate each, differently activated macrophages GSM411186 GSM411187 PPAR GSE16385c primary IFNg/TNFa activated monocytes treated with 1mM rosiglitazone, a PPARg agonist activation 4 h 1 replicate each, differently activated macrophages GSM411188 GSM411189 PPAR GSE16386a primary IL4 activated monocytes treated with 100 ng/ml rosiglitazone, a PPARg agonist activation 6 h 2 replicates each, 2 donors GSM411223,GSM411224 GSM411225,GSM411226 PPAR GSE16386b primary IL4 activated monocytes treated with 100 ng/ml rosiglitazone, a PPARg agonist activation 6 h 2 replicates each, 2 donors GSM411227,GSM411228 GSM411229,GSM411230 PPAR GSE17251a primary hepatocytes treated with 50µM Wy14643, a PPARa agonist activation 6 h 1 replicate each, 6 donors GSM432140 GSM432139 PPAR GSE17251b primary hepatocytes treated with 50µM Wy14643, a PPARa agonist activation 6 h 1 replicate each, 6 donors GSM432144 GSM432143 PPAR GSE17251c primary hepatocytes treated with 50µM Wy14643, a PPARa agonist activation 6 h 1 replicate each, 6 donors GSM432148 GSM432147 PPAR GSE17251d primary hepatocytes treated with 50µM Wy14643, a PPARa agonist activation 6 h 1 replicate each, 6 donors GSM432152 GSM432151 PPAR GSE17251e primary hepatocytes treated with 50µM Wy14643, a PPARa agonist activation 6 h 1 replicate each, 6 donors GSM432156 GSM432155 PPAR GSE17251f primary hepatocytes treated with 50µM Wy14643, a PPARa agonist activation 6 h 1 replicate each, 6 donors GSM432160 GSM432159 PPAR GSE25547 HepG2 cells treated with 100nM GW7647, a PPARa agonist activation 6 h 3 replicates each GSM627985,GSM627986,GSM627987 GSM627988,GSM627989,GSM627990 PPAR GSE5258PPAR MCF7 cells treated with 10µM rosiglitazone, a PPARg agonist activation 6 h 2 replicates each GSM119067,GSM119103 GSM119249,GSM119206 PPAR GSE8658a monocyte derived dendritic cells treated with 1µM rosiglitazone, a PPARg agonist activation 6 h 1 replicate each, 6 donors GSM214750 GSM214751 PPAR GSE8658b monocyte derived dendritic cells treated with 1µM rosiglitazone, a PPARg agonist activation 6 h 1 replicate each, 6 donors GSM214752 GSM214753 PPAR GSE8658c monocyte derived dendritic cells treated with 1µM rosiglitazone, a PPARg agonist activation 6 h 1 replicate each, 6 donors GSM214754 GSM214755 PPAR GSE8658d monocyte derived dendritic cells treated with 1µM rosiglitazone, a PPARg agonist activation 6 h 1 replicate each, 6 donors GSM214756 GSM214763 PPAR GSE8658e monocyte derived dendritic cells treated with 1µM rosiglitazone, a PPARg agonist activation 6 h 1 replicate each, 6 donors GSM214764 GSM214766 PPAR GSE8658f monocyte derived dendritic cells treated with 1µM rosiglitazone, a PPARg agonist activation 6 h 1 replicate each, 6 donors GSM214767 GSM214769 RAR GSE14426a pancreatic stellate cell line treated with 1µM all-trans retinoid acid activation 0.5 h 3 replicates each, part of time series, time resolved controls GSM360282,GSM360283,GSM360284 GSM360285,GSM360286,GSM360287 RAR GSE14426b pancreatic stellate cell line treated with 1µM all-trans retinoid acid activation 4 h 3 replicates each, part of time series, time resolved controls GSM360288,GSM360289,GSM360290 GSM360291,GSM360292,GSM360293 RAR GSE14500a HL60 neutrophil progenitor cells treated with 1µM all-trans retinoid acid activation 2 h 1 replicate each, part of time series, time respective control GSM362155 GSM362143 RAR GSE14500b HL60 neutrophil progenitor cells treated with 1µM all-trans retinoid acid activation 4 h 1 replicate each, part of time series, time respective control GSM362156 GSM362144 RAR GSE19201 NB4 cells treated with all-trans retinoid acid activation 4 h 1 replicate each GSM475993 GSM475994 RAR GSE22298a primary epidermal karatinocytes treated with 1µM all-trans retinoid acid activation 1 h 1 replicate each, part of time series, time resolved controls GSM555039 GSM555044 RAR GSE22298b primary epidermal karatinocytes treated with 1µM all-trans retinoid acid activation 4 h 1 replicate each, part of time series, time resolved controls GSM555040 GSM555045 RAR GSE24731 HL60 leukemia cells treated with 100nM retinoid acid activation 4 h 4 replicates each, contain control vector GSM609174,GSM609175,GSM609176,GSM609177 GSM609185,GSM609186,GSM609187,GSM609188 RAR GSE29213 NB4 leukemia cells treated with 10nM retinoid acid activation 4 h 4 replicates each, contain control vector GSM722534,GSM722535,GSM722536,GSM722537 GSM722538,GSM722539,GSM722540,GSM722541 TGFb GSE13837a1 primary synovial fibroblasts treated with 10ng/ml TGF-beta activation 1 h 1 replicate each, part of time series, several patients GSM347191 GSM347194 TGFb GSE13837a2 primary synovial fibroblasts treated with 10ng/ml TGF-beta activation 2 h 1 replicate each, part of time series, several patients GSM347191 GSM347197 TGFb GSE13837a3 primary synovial fibroblasts treated with 10ng/ml TGF-beta activation 4 h 1 replicate each, part of time series, several patients GSM347191 GSM347330 TGFb GSE13837b1 primary synovial fibroblasts treated with 10ng/ml TGF-beta activation 1 h 1 replicate each, part of time series, several patients GSM347340 GSM347733 TGFb GSE13837b2 primary synovial fibroblasts treated with 10ng/ml TGF-beta activation 2 h 1 replicate each, part of time series, several patients GSM347340 GSM347734 TGFb GSE13837b3 primary synovial fibroblasts treated with 10ng/ml TGF-beta activation 4 h 1 replicate each, part of time series, several patients GSM347340 GSM347735 TGFb GSE13837c1 primary synovial fibroblasts treated with 10ng/ml TGF-beta activation 1 h 1 replicate each, part of time series, several patients GSM347799 GSM347765 TGFb GSE13837c2 primary synovial fibroblasts treated with 10ng/ml TGF-beta activation 2 h 1 replicate each, part of time series, several patients GSM347799 GSM347766 TGFb GSE13837c3 primary synovial fibroblasts treated with 10ng/ml TGF-beta activation 4 h 1 replicate each, part of time series, several patients GSM347799 GSM347767 TGFb GSE13837d1 primary synovial fibroblasts treated with 10ng/ml TGF-beta activation 1 h 1 replicate each, part of time series, several patients GSM347845 GSM347841 TGFb GSE13837d2 primary synovial fibroblasts treated with 10ng/ml TGF-beta activation 2 h 1 replicate each, part of time series, several patients GSM347845 GSM347842 TGFb GSE13837d3 primary synovial fibroblasts treated with 10ng/ml TGF-beta activation 4 h 1 replicate each, part of time series, several patients GSM347845 GSM347843 TGFb GSE13837e1 primary synovial fibroblasts treated with 10ng/ml TGF-beta activation 1 h 1 replicate each, part of time series, several patients GSM348030 GSM348024 TGFb GSE13837e2 primary synovial fibroblasts treated with 10ng/ml TGF-beta activation 2 h 1 replicate each, part of time series, several patients GSM348030 GSM348027 TGFb GSE13837e3 primary synovial fibroblasts treated with 10ng/ml TGF-beta activation 4 h 1 replicate each, part of time series, several patients GSM348030 GSM348028 TGFb GSE14491 MDA-MB-231 metastatic breast cell line treated with 5µg/ml TGF-beta activation 3 h 4 replicate each, transfected with shGFP GSM361954,GSM361955,GSM361956,GSM361957 GSM361958,GSM361959,GSM361960,GSM361961 TGFb GSE1724 lung fibroblasts treated with 4 ng/ml TGF-beta activation 4 h 3 replicates each GSM29911,GSM29915,GSM29918 GSM29913,GSM29916,GSM29919 TGFb GSE17708a A549 lung carcinoma cell line treated with 5ng/ml TGF-beta activation 0.5 h 3 replicates each, part of time series GSM442026,GSM442027,GSM442028 GSM442029,GSM442030,GSM442031 TGFb GSE17708b A549 lung carcinoma cell line treated with 5ng/ml TGF-beta activation 1 h 3 replicates each, part of time series GSM442026,GSM442027,GSM442028 GSM442032,GSM442033,GSM442034 TGFb GSE17708c A549 lung carcinoma cell line treated with 5ng/ml TGF-beta activation 2 h 3 replicates each, part of time series GSM442026,GSM442027 GSM442035,GSM442036 TGFb GSE17708d A549 lung carcinoma cell line treated with 5ng/ml TGF-beta activation 4 h 3 replicates each, part of time series GSM442026,GSM442027,GSM442028 GSM442037,GSM442038,GSM442039 TGFb GSE17860 osteoblast cell line treated with 10ng/ml TGF-beta activation 6 h 3 replicates each GSM445699,GSM445701,GSM445703 GSM445698,GSM445700,GSM445702 TGFb GSE1802a human umbilical cord blood CD34+ cells treated with TGF-beta activation 2 h 3 replicates each, part of time series GSM31092,GSM31093,GSM31094 GSM31096,GSM31097,GSM31098 TGFb GSE1802b human umbilical cord blood CD34+ cells treated with TGF-beta activation 4 h 4 replicates each, part of time series GSM31092,GSM31093,GSM31094,GSM31094 GSM31099,GSM31100,GSM31101,GSM31102 TGFb GSE1805a M091 treated with 10 ng/ml TGF-beta activation 2 h 3 replicates each, part of time series GSM31117,GSM31119,GSM31120 GSM31122,GSM31123,GSM31124 TGFb GSE1805b M091 treated with TGF-beta activation 4 h 2 replicates each, part of time series GSM31117,GSM31119 GSM31126,GSM31127 TGFb GSE23935a primary glioblastoma treated with LY2109761, TGF-beta receptor inhibitor inhibition 3 h 1 replicate each GSM589933 GSM589934 TGFb GSE23935b primary glioblastoma treated with LY2109761, TGF-beta receptor inhibitor inhibition 3 h 1 replicate each GSM589935 GSM589936 TGFb GSE23935c primary glioblastoma treated with LY2109761, TGF-beta receptor inhibitor inhibition 3 h 1 replicate each GSM589937 GSM589938 TGFb GSE23935d primary glioblastoma treated with LY2109761, TGF-beta receptor inhibitor inhibition 3 h 1 replicate each GSM589939 GSM589940 TGFb GSE23935e primary glioblastoma treated with LY2109761, TGF-beta receptor inhibitor inhibition 3 h 1 replicate each GSM589941 GSM589942 TGFb GSE23935f primary glioblastoma treated with LY2109761, TGF-beta receptor inhibitor inhibition 3 h 1 replicate each GSM589943 GSM589944 TGFb GSE23935g primary glioblastoma treated with LY2109761, TGF-beta receptor inhibitor inhibition 3 h 1 replicate each GSM589945 GSM589946 TGFb GSE23935h primary glioblastoma treated with LY2109761, TGF-beta receptor inhibitor inhibition 3 h 1 replicate each GSM589947 GSM589948 TGFb GSE23935i primary glioblastoma treated with LY2109761, TGF-beta receptor inhibitor inhibition 3 h 1 replicate each GSM589949 GSM589950 TGFb GSE23935j primary glioblastoma treated with LY2109761, TGF-beta receptor inhibitor inhibition 3 h 1 replicate each GSM589951 GSM589952 TGFb GSE23935k primary glioblastoma treated with LY2109761, TGF-beta receptor inhibitor inhibition 3 h 1 replicate each GSM589953 GSM589954 TGFb GSE27526 A2780 treated with 10ng/ml TGF-beta1 activation 3 h 3 replicates each GSM687585,GSM687586,GSM687587 GSM687582,GSM687583,GSM687584 TGFb GSE28590 HepG2 hepatoblastoma cells treated with 3ng/ml TGF-beta activation 1.5 h 1 replicate each GSM707672 GSM707673 TGFb GSE30004a primary vascular smooth muscle cells treated with 1ng/ml TGF-beta activation 6 h 3 replicates each GSM742529,GSM742533,GSM742537 GSM742517,GSM742521,GSM742525 TGFb GSE30004b primary vascular smooth muscle cells treated with 1ng/ml TGF-beta activation 6 h 3 replicates each GSM742530,GSM742534,GSM742538 GSM742518,GSM742522,GSM742526 TGFb GSE30004c primary vascular smooth muscle cells treated with 1ng/ml TGF-beta activation 6 h 3 replicates each GSM742531,GSM742535,GSM742539 GSM742519,GSM742523,GSM742527 TGFb GSE5150a CD34+ hematopoietic stem/progenitor cells treated with TGF-beta activation 2 h 1 replicate each, part of time series GSM116315 GSM116316 TGFb GSE5150b CD34+ hematopoietic stem/progenitor cells treated with TGF-beta activation 4 h 1 replicate each, part of time series GSM116315 GSM116317 TGFb GSE5151 dendritic cells treated with 10 ng/ml TGF-beta1 activation 4 h 1 replicate GSM116323 GSM116324 TGFb GSE6653a IOSE - immortalized ovarian surface epithelial cells treated with TGF-beta1 activation 3 h 2 replicates each, part of time series GSM154124,GSM154125 GSM154126,GSM154127 TGFb GSE6653b IOSE - immortalized ovarian surface epithelial cells treated with TGF-beta1 activation 6 h 2 replicates each, part of time series GSM154124,GSM154125 GSM154128,GSM154129 TGFb GSE8730a odontoblasts treated with TGF-beta1 activation 1 h 1 replicate GSM216537 GSM216538 TGFb GSE8730b pulp tissue treated with TGF-beta1 activation 1 h 1 replicate, part of time series GSM216541 GSM216546 TGFb GSE8730c pulp tissue treated with TGF-beta1 activation 5 h 1 replicate, part of time series GSM216543 GSM216547 TNFa GSE11115 U3OS cells expressing additional estrogen receptor treated with TNFa activation 1h h 3-4 replicates each, doxycyline induction of ER expression GSM280387,GSM280388,GSM280389 GSM280379,GSM280380,GSM280381,GSM280382 TNFa GSE13206a HeLa cells treated with 5 ng/ml TNFa activation 1.5 h 1 replicate each, part of time series, shControl transfected GSM333597 GSM333591 TNFa GSE13206b HeLa cells treated with 5 ng/ml TNFa activation 6 h 1 replicate each, part of time series, shControl transfected GSM333597 GSM333594 TNFa GSE13837a synovial fibroblasts, female, age 65, rheumatoid arthritis treated with TNFa 10 ng/ml activation 1 h always compared to the 0 h time point GSM347191,GSM347193 GSM347196 TNFa GSE13837b synovial fibroblasts, female, age 65, rheumatoid arthritis treated with TNFa 10 ng/ml activation 2 h always compared to the 0 h time point GSM347191,GSM347193 GSM347328 TNFa GSE13837c synovial fibroblasts, female, age 65, rheumatoid arthritis treated with TNFa 10 ng/ml activation 4 h always compared to the 0 h time point GSM347191,GSM347193 GSM347332 TNFa GSE13837d synovial fibroblasts, male, age 56, osteoarthritis treated with TNFa 10 ng/ml activation 1 h always compared to the 0 h time point GSM347340,GSM347342 GSM347737 TNFa GSE13837e synovial fibroblasts, male, age 56, osteoarthritis treated with TNFa 10 ng/ml activation 2 h always compared to the 0 h time point GSM347340,GSM347342 GSM347738 TNFa GSE13837f synovial fibroblasts, male, age 56, osteoarthritis treated with TNFa 10 ng/ml activation 4 h always compared to the 0 h time point GSM347340,GSM347342 GSM347739 TNFa GSE13837g synovial fibroblasts, male, age 65, osteoarthritis treated with TNFa 10 ng/ml activation 1 h always compared to the 0 h time point GSM347764,GSM347745 GSM347746 TNFa GSE13837h synovial fibroblasts, male, age 65, osteoarthritis treated with TNFa 10 ng/ml activation 2 h always compared to the 0 h time point GSM347764,GSM347745 GSM347747 TNFa GSE13837i synovial fibroblasts, male, age 65, osteoarthritis treated with TNFa 10 ng/ml activation 4 h always compared to the 0 h time point GSM347764,GSM347745 GSM347748 TNFa GSE13837j synovial fibroblasts, female, age 57, osteoarthritis treated with TNFa 10 ng/ml activation 1 h always compared to the 0 h time point GSM347799,GSM347840 GSM347819 TNFa GSE13837k synovial fibroblasts, female, age 57, osteoarthritis treated with TNFa 10 ng/ml activation 2 h always compared to the 0 h time point GSM347799,GSM347840 GSM347837 TNFa GSE13837l synovial fibroblasts, female, age 57, osteoarthritis treated with TNFa 10 ng/ml activation 4 h always compared to the 0 h time point GSM347799,GSM347840 GSM347838 TNFa GSE13837m synovial fibroblasts, female, age 57, rheumatoid arthritis treated with TNFa 10 ng/ml activation 1 h always compared to the 0 h time point GSM347845,GSM348023 GSM348017 TNFa GSE13837n synovial fibroblasts, female, age 57, rheumatoid arthritis treated with TNFa 10 ng/ml activation 2 h always compared to the 0 h time point GSM347845,GSM348023 GSM348018 TNFa GSE13837o synovial fibroblasts, female, age 57, rheumatoid arthritis treated with TNFa 10 ng/ml activation 4 h always compared to the 0 h time point GSM347845,GSM348023 GSM348020 TNFa GSE13837p synovial fibroblasts, female, age 67, rheumatoid arthritis treated with TNFa 10 ng/ml activation 1 h always compared to the 0 h time point GSM348030,GSM348037 GSM348031 TNFa GSE13837q synovial fibroblasts, female, age 67, rheumatoid arthritis treated with TNFa 10 ng/ml activation 2 h always compared to the 0 h time point GSM348030,GSM348037 GSM348034 TNFa GSE13837r synovial fibroblasts, female, age 67, rheumatoid arthritis treated with TNFa 10 ng/ml activation 4 h always compared to the 0 h time point GSM348030,GSM348037 GSM348035 TNFa GSE1474a CaCo-2 (Colon cell line) treated with TNFa activation 4 h 3 replicates each GSM24832,GSM24833,GSM24834 GSM24841,GSM24842,GSM24843 TNFa GSE1474b T84 treated with TNFa activation 4 h 3 replicates each GSM24844,GSM24845,GSM24846 GSM24853,GSM24854,GSM24855 TNFa GSE1541a A549 (Alveolar Epithelial Cells line) treated with TNFa 20 ng/ml activation 1 h GSM26477,GSM26478 GSM26489,GSM26490 TNFa GSE1541b A549 (Alveolar Epithelial Cells line) treated with TNFa 20 ng/ml activation 4 h GSM26479,GSM26480 GSM26491,GSM26492 TNFa GSE16251aTNFa primary PBMCs treated with TNFa activation 0.5 h 1 replicate each, part of time series, time respective control GSM409180 GSM409184 TNFa GSE16251bTNFa primary PBMCs treated with TNFa activation 1 h 1 replicate each, part of time series, time respective control GSM409182 GSM409140 TNFa GSE16251cTNFa primary PBMCs treated with TNFa activation 4 h 1 replicate each, part of time series, time respective control GSM409178 GSM409174 TNFa GSE16650 Beas-B2 (Human Bronchial Epithelial Cells) treated with TNFa 20 ng/ml activation 4 h 2 replicates each GSM417770,GSM417776 GSM417774,GSM417780 TNFa GSE21727TNFa trabecular bone cells treated with TNFa activation 2 h 3 replicates each, time respective control GSM542107,GSM542108,GSM542109 GSM542104,GSM542105,GSM542106 TNFa GSE22807 DU145 prostate cancer cells treated with 10 ng/ml TNFa activation 1.5 h 2 replicates each GSM563798,GSM563799 GSM563802,GSM563803 TNFa GSE2489a Epidermis Keratinocytes treated with TNFa activation 1 h GSM47302,GSM47304 GSM47311 TNFa GSE2489b Epidermis Keratinocytes treated with TNFa activation 4 h GSM47305,GSM47306 GSM47312 TNFa GSE2624a human cervical epithelioid carcinoma cell line HeLa expressing tTA pBI-EGFP- IkBa Mut treated with TNFa 25ng/ml and Doxycyline (2 mg/ml) to take IKB-inhibition away activation 1 h mutant cell line GSM50301,GSM50310,GSM50319,GSM50327 GSM50302,GSM50312,GSM50320,GSM50328 TNFa GSE2624b human cervical epithelioid carcinoma cell line HeLa expressing tTA pBI-EGFP- IkBa Mut treated with TNFa 25ng/ml and Doxycyline (2 mg/ml) to take IKB-inhibition away activation 3 h mutant cell line GSM50301,GSM50310,GSM50319,GSM50327 GSM50304,GSM50313,GSM50321,GSM50329 TNFa GSE2638 HMECs treated with 2ng/ml TNFa activation 5 h 3 replicates each GSM50771,GSM50772,GSM50773 GSM50774,GSM50775,GSM50776 TNFa GSE2639 HUVECs treated with 2ng/ml TNFa activation 5 h 4 replicates each GSM50777,GSM50778,GSM50779,GSM50780 GSM50781,GSM50782,GSM50783,GSM50784 TNFa GSE26868a HeLa cells treated with 10 ng/ml TNFa activation 2 h 2 replicates each, comparison 2 cell lines GSM661462,GSM661463 GSM661464,GSM661465 TNFa GSE26868b THP1 cells treated with 10 ng/ml TNFa activation 2 h 3 replicates each, comparison 2 cell lines GSM661466,GSM661467,GSM661468 GSM661469,GSM661470,GSM661471 TNFa GSE28548 HEK293 cells treated with TNFa activation 1 h 3 replicates each GSM707024,GSM707025,GSM707026 GSM707027,GSM707028,GSM707029 TNFa GSE516 human arthritic synoviocytes treated with TNFa activation 4 h GSM7735 GSM7736 TNFa GSE8166 treated with TNFa 1ng/ml cultured in M199 medium activation 3 h GSM202176 GSM202183 TNFa GSE9055a HUVEC (Human umbilical vein cells) treated with TNFa 10 ng/ml after 18 h serum starvation activation 0.5 h time series every 15 min until 8 h GSM229941 GSM229910 TNFa GSE9055b HUVEC (Human umbilical vein cells) treated with TNFa 10 ng/ml after 18 h serum starvation activation 1 h time series every 15 min until 8 h GSM229941 GSM229912 TNFa GSE9055c HUVEC (Human umbilical vein cells) treated with TNFa 10 ng/ml after 18 h serum starvation activation 2 h time series every 15 min until 8 h GSM229941 GSM229916 TNFa GSE9055d HUVEC (Human umbilical vein cells) treated with TNFa 10 ng/ml after 18 h serum starvation activation 4 h time series every 15 min until 8 h GSM229941 GSM229924 Trail GSE32441a HT1080 fibrosarcoma cells treated with 50 ng/ml TRAIL activation 6 h 1 replicate each, control and treated cells were additionally treated with 0.25 µg/ml doxorubicin GSM802717 GSM802719 Trail GSE32441b HT1080 fibrosarcoma cells treated with 50 ng/ml TRAIL activation 6 h 1 replicate each, control and treated cells were additionally treated with 4 µg/ml trabectedin GSM802713 GSM802715 Trail GSE32441c HT1080 fibrosarcoma cells treated with 50 ng/ml TRAIL activation 6 h 1 replicate each, control and treated cells were additionally treated with 1.5 µg/ml mafosfamide GSM802721 GSM802723 Trail GSE8346 T4-2 breat epithelial cells treated with 1 µg/ml TRAIL activation 4 h 4 replicates each, contain control vector, 3D culture GSM206809,GSM206827,GSM206828,GSM206829 GSM206834,GSM206835,GSM206836,GSM206837 VEGF GSE10778aVEGF HUVEC (human umbilical vein endothelial cells) treatment with 100ng VEGF activation 30 min time series (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B GSM272113 GSM272114 VEGF GSE10778bVEGF HUVEC (human umbilical vein endothelial cells) treatment with 100ng VEGF activation 1 h time series (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B GSM272113 GSM272115 VEGF GSE10778cVEGF HUVEC (human umbilical vein endothelial cells) treatment with 100ng VEGF activation 2.5 h time series (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B GSM272113 GSM272116 VEGF GSE10778d HUVEC (human umbilical vein endothelial cells) treatment with 100ng VEGF activation 30 min time series (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B GSM272122 GSM272123 VEGF GSE10778e HUVEC (human umbilical vein endothelial cells) treatment with 100ng VEGF activation 1 h time series (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B GSM272122 GSM272124 VEGF GSE10778f HUVEC (human umbilical vein endothelial cells) treatment with 100ng VEGF activation 2.5 h time series (0.5, 1, 2.5, 6 h), 2 Chips HG-U133A and B GSM272122 GSM272125 VEGF GSE11228a LEC (Human dermal lymphatic endothelial cells) treatment with VEGF-A165 (20ng/ml) activation 1 h time series (1, 4, 8, 24 h) GSM283080,GSM283081,GSM283082 GSM283083,GSM283084,GSM283085 VEGF GSE11228b LEC (Human dermal lymphatic endothelial cells) treatment with VEGF-A165 (20 ng/ml) activation 4 h time series (1, 4, 8, 24 h) GSM283080,GSM283081,GSM283082 GSM283086,GSM283087,GSM283088 VEGF GSE11228c LEC (Human dermal lymphatic endothelial cells) treatment with VEGF-C (500 ng/ml) activation 1 h time series (1, 4, 8, 24 h) GSM283080,GSM283081,GSM283082 GSM283095,GSM283096,GSM283097 VEGF GSE11228d LEC (Human dermal lymphatic endothelial cells) treatment with VEGF-C (500 ng/ml) activation 4 h time series (1, 4, 8, 24 h) GSM283080,GSM283081,GSM283082 GSM283098,GSM283099,GSM283100 VEGF GSE15464a HUVECs treated with 100ng/ml VEGF-A165 activation 30 min 1 replicate, part of time series GSM385333 GSM385338 VEGF GSE15464b HUVECs treated with 100ng/ml VEGF-A165 activation 60 min 1 replicate, part of time series GSM385333 GSM385350 VEGF GSE15464c HUVECs treated with 100ng/ml VEGF-A165 activation 150 min 1 replicate, part of time series GSM385333 GSM385353 VEGF GSE17777 HMVECs treated with 100pg/ml VEGF activation 4 h 1 replicate GSM443878 GSM443879 VEGF GSE18913a HUVECs treated with VEGF activation 1 h 3 replicates, part of time series GSM468603,GSM468604,GSM468621 GSM468609,GSM468610,GSM468622 VEGF GSE18913b HUVECs treated with VEGF activation 4 h 3 replicates, part of time series GSM468603,GSM468604,GSM468621 GSM468615,GSM468616,GSM468623 VEGF GSE19335 HUVECs treated with 50ng/ml VEGF activation 30 min 2 replicates GSM595674,GSM595675 GSM595676,GSM595677 VEGF GSE3891a HMVEC (Human microvascular endothelial cells) VEGF treatment activation 30 min time series 30 min, 1, 2, 4 h GSM88897 GSM88898 VEGF GSE3891b HMVEC (Human microvascular endothelial cells) VEGF treatment activation 1 h time series 30 min, 1, 2, 4 h GSM88897 GSM88899 VEGF GSE3891c HMVEC (Human microvascular endothelial cells) VEGF treatment activation 2 h time series 30 min, 1, 2, 4 h GSM88897 GSM88900 VEGF GSE3891d HMVEC (Human microvascular endothelial cells) VEGF treatment activation 4 h time series 30 min, 1, 2, 4 h GSM88897 GSM88901 VEGF GSE3891e HMVEC (Human microvascular endothelial cells) VEGF treatment activation 30 min time series 30 min, 1, 2, 4 h GSM88907 GSM88908 VEGF GSE3891f HMVEC (Human microvascular endothelial cells) VEGF treatment activation 1 h time series 30 min, 1, 2, 4 h GSM88907 GSM88909 VEGF GSE3891g HMVEC (Human microvascular endothelial cells) VEGF treatment activation 2 h time series 30 min, 1, 2, 4 h GSM88907 GSM88910 VEGF GSE3891h HMVEC (Human microvascular endothelial cells) VEGF treatment activation 4 h time series 30 min, 1, 2, 4 h GSM88907 GSM88911 VEGF GSE837a HUVECs treated with VEGF activation 4 h 1 replicate, part of 3 different isolates GSM12900 GSM12901 VEGF GSE837b HUVECs treated with VEGF activation 4 h 1 replicate, part of 3 different isolates GSM12902 GSM12903 VEGF GSE837c HUVECs treated with VEGF activation 4 h 1 replicate, part of 3 different isolates GSM12904 GSM12905 Wnt GSE106755a human fetal liver progenitor cells 100ng/ml Wnt3a activation 12 h arrays are background corrected thus containing zeros!!!! GSM2849887,GSM2849888,GSM2849889 GSM2849890,GSM2849891,GSM2849892 Wnt GSE106755b SV40-large T -immortalized human fetal liver cells 100ng/ml Wnt3a activation 12 h arrays are background corrected thus containing zeros!!!! GSM2849896,GSM2849897,GSM2849898 GSM2849899,GSM2849900,GSM2849901 Wnt GSE114059 colorectal cancer organoid PTO 19T Wnt signalling inhibitor PRI-724 inhibition 72 h 2 replicates each, Control is MEKi Trametinib supposedly inducing wnt signalling, Treatment is MEKi+Wnti GSM3131706,GSM3131707 GSM3131708,GSM3131709 Wnt GSE11916 Huh7 (hepatocellular carcinoma derived) High TCF activity Huh7 cell line was compared to control Huh7 cell line (TCF the crucial transcription factor for Wnt) activation not specified constitutive activation GSM301104,GSM301105,GSM301106 GSM301119,GSM301132,GSM301133 Wnt GSE14107a parental PC9 (Lung adenocarcinoma cell line) Wnt3a stimulation after serum starvation (0.2 %) activation 3 h GSM354009,GSM354010 GSM354011,GSM354012 Wnt GSE14107b parental H2030 (Lung adenocarcinoma cell line) Wnt3a stimulation after serum starvation (0.2 %) activation 3 h GSM354017,GSM354018 GSM354019,GSM354020 Wnt GSE1473 HEK293 (kidney cell) infected with RCAS-beta-cateninS37A or RCAS-GFP activation not specified late and early response expected GSM24862,GSM24863,GSM24864,GSM24865 GSM24858,GSM24859,GSM24860,GSM24861 Wnt GSE18560 colorectal cancer cell line Ls174T siRNA-mediated knockdown of beta-Catenin inhibition 72 h 3 replicates each GSM461951,GSM461953,GSM461944 GSM461942,GSM461947,GSM461949 Wnt GSE26351 mobilized periphal blood CD34+ cells 0.5 µM BIO (GSK3 inhibitor) activation 2 h 3 replicates, BIO activates WNT pathway GSM647150,GSM647151,GSM647152 GSM647153,GSM647154,GSM647155 Wnt GSE27313 mesenchymal stem cells treated with Wnt3a activation 6 h 1 replicate each GSM675170 GSM675171 Wnt GSE35272 Colorectal cancer cell line DLD-1 DKK1 overexpression (Wnt ligand antagonist) inhibition 24 h 3 replicates GSM864825,GSM864826,GSM864827 GSM864828,GSM864829,GSM864830 Wnt GSE37964 Colorectal cell line DLD-1 dominant negative TCF-1E inducible expression controlled by 1µg/ml Doxycyclin inhibition 8 h 3-4 replicates GSM931041,GSM931042,GSM931043,GSM931044 GSM931035,GSM931036,GSM931037 Wnt GSE38893 MDA-MB-468 Breast cancer cell line Wnt3a activation 8 h 2 replicates GSM951573,GSM951579 GSM951576,GSM951582 Wnt GSE42071 Megacaryocytic cells CHRF-288-11 (Childhood acute megakaryoblastic leukemia) Wnt3a activation 8 h 3 replicates GSM1031987,GSM1031980,GSM1031981 GSM1031986,GSM1031978,GSM1031983 Wnt GSE44097a Colorectal cancer cell line SW480 beta-catenin siRNA inhibition 48 h 3 replicates, also second cell line measured GSM1078893,GSM1078894,GSM1078895 GSM1078896,GSM1078897,GSM1078898 Wnt GSE44097b Colorectal cancer cell line DLD1 beta-catenin siRNA inhibition 48 h 3 replicates, also second cell line measured GSM1078887,GSM1078888,GSM1078889 GSM1078890,GSM1078891,GSM1078892 Wnt GSE46465a liver cancer cell line HepG2 expression of dominant negative form of TCF4 inhibition 48 h 4 replicates, second cell line measured by same lab GSM1130672,GSM1130673,GSM1130674,GSM1130675 GSM1130676,GSM1130677,GSM1130678,GSM1130679 Wnt GSE46465b colon cancer cell line LS174T expression of dominant negative form of TCF4 inhibition 48 h 3 replicates, second cell line measured by same lab GSM1130666,GSM1130667,GSM1130668 GSM1130669,GSM1130670,GSM1130671 Wnt GSE56896 colorectal cancer cell line LS174T expressed a tamoxifen-inducible β-catenin-binding domain of TCF4 (dominant negative) inhibition 36 h 3 replicates each GSM1370840,GSM1370841,GSM1370842 GSM1370843,GSM1370844,GSM1370845 Wnt GSE58525 Glioblastoma cell line LN-229 Wnt Inhibitory Factor 1 (WIF1) overexpression inhibition 48 h 2 replicates GSM1412991,GSM1412992 GSM1412993,GSM1412994 Wnt GSE59400 memory T cells stimulated with antiCD3/CD28 3µM TWS119 (GSK3-beta inhibitor) activation agilent single colour array, no paper published GSM1436334,GSM1436335,GSM1436336 GSM1436331,GSM1436332,GSM1436333 Wnt GSE61275 AML cells OCI-AML 100-200nM BC2059 (beta Catenin antagonist) inhibition 8 h no replicate GSM1501289 GSM1501288 Wnt GSE61687 Gastric cancer cell line AGS beta-Catenin siRNA inhibition 48 h 3 replicates, no paper, same lab as GSE62060 GSM1511325,GSM1511326,GSM1511327 GSM1511328,GSM1511329,GSM1511330 Wnt GSE62060 Gastric cancer cell line YCC3 beta-Catenin siRNA inhibition 48 h 3 replicates, no paper GSM1519062,GSM1519063,GSM1519064 GSM1519065,GSM1519066,GSM1519067 Wnt GSE65238a Triple negative breast cancer cell MDA_MB-468 Wnt3a activation 6 h 3 replicates GSM1590550,GSM1590562,GSM1590574 GSM1590551,GSM1590563,GSM1590575 Wnt GSE65238b Triple negative breast cancer cell MDA_MB-468 Wnt3a activation 12 h 3 replicates GSM1590552,GSM1590564,GSM1590576 GSM1590553,GSM1590565,GSM1590577 Wnt GSE65238c Triple negative breast cancer cell HCC38 Wnt3a activation 6 h 3 replicates GSM1590556,GSM1590568,GSM1590580 GSM1590557,GSM1590569,GSM1590581 Wnt GSE65238d Triple negative breast cancer cell HCC38 Wnt3a activation 12 h 3 replicates GSM1590558,GSM1590570,GSM1590582 GSM1590559,GSM1590571,GSM1590583 Wnt GSE67571a lung cancer cell line A549 LM (Spheres transferred to adhesive tissue culture) Wnt3a activation 24 h no replicate GSM1649833 GSM1649834 Wnt GSE67571b lung cancer cell line A549 sphere HM20 selected 20 times for invasiveness Wnt3a activation 24 h no replicate GSM1649835 GSM1649836 Wnt GSE97625 human embryonic stem cells 5µM GSK3-ß inhibitor CHIR99021 activation 4 h no replicates, arrays are background corrected thus containing zeros!!!! GSM2573320 GSM2573322